"","pmid","doi","title","abstract","year","month","day","jabbrv","journal","keywords","lastname","firstname","address","email"
"1","33711296","10.1016/S0140-6736(21)00503-1","Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development.","The research and development (R&amp;D) ecosystem has evolved over the past decade to include pandemic infectious diseases, building on experience from multiple recent outbreaks. Outcomes of this evolution have been particularly evident during the COVID-19 pandemic with accelerated development of vaccines and monoclonal antibodies, as well as novel clinical trial designs. These products were developed, trialled, manufactured, and authorised for use in several countries within a year of the pandem","2021","03","12","Lancet","Lancet (London, England)",NA,"Lurie","Nicole","Coalition for Epidemic Preparedness Innovations, Oslo, Norway",NA
"2","33711085","10.2196/22470","Predicting Health Disparities in Regions at Risk of Severe Illness to Inform Health Care Resource Allocation During Pandemics: Observational Study.","Pandemics including COVID-19 have disproportionately affected socioeconomically vulnerable populations. Our objective was to create a repeatable modeling process to identify regional population centers with pandemic vulnerability. Using readily available COVID-19 and socioeconomic variable data sets, we used stepwise linear regression techniques to build predictive models during the early days of the COVID-19 pandemic. The models were validated later in the pandemic timeline using actual COVID-1","2021","03","14","JMIRx Med","JMIRx med","COVID-19; SARS-CoV-2; coronavirus; health care resource allocation; pandemic; predictive model; socioeconomic status","Fusillo","Tara","John F Kennedy High School Bellmore, NY United States",NA
"3","33709292","10.1007/s11695-021-05339-4","Eighty-Seven Consecutive Sleeve Gastrectomies Between the Two Peaks of the Covid-19 Pandemic. An Opening-Phase Experience.","During the Covid-19 pandemic, the outcome of symptomatic Covid-19 infection occurring early after elective operations is reportedly associated with fatalities. Incidence is unknown and data on bariatric practice is scarce. Covid-19 exposure status and outcomes of sleeve gastrectomy (SG) between the first two peaks of the pandemic are prospectively evaluated. During our &quot;opening-phase,&quot; candidates for SG were enrolled after written informed consent was obtained which specifically emphas","2021","03","14","Obes Surg","Obesity surgery","Covid-19; SARS-CoV-2; complication; elective surgery; sleeve gastrectomy","Yerdel","Mehmet Ali","..stanbul Bariatrics, Obesity and Advanced Laparoscopy Center, Fulya Mah. Ye..il..imen Sok. 12/407 34394, ..i..li, ..stanbul, Turkey. yerdel@yerdel","yerdel@yerdel.com"
"4","33707061","10.1016/j.vaccine.2021.02.007","A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.","Vaccines are urgently needed to prevent the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the safety and immunogenicity of vaccine candidate mRNA-1273, encoding the prefusion-stabilized spike protein of SARS-CoV-2. This phase 2, randomized, observer-blind, placebo-controlled trial was conducted at 8 sites in the USA, in healthy adults aged.....18..years with no known history or risk of SARS-CoV-2 infection, and had not previously received an investiga","2021","03","14","Vaccine","Vaccine","COVID-19; Immunogenicity; Phase 2; SARS-CoV-2; Safety; Vaccine; mRNA-1273","Chu","Laurence","Benchmark Research, 3100 Red River St #2, Austin, TX 78705, United States",NA
"5","33705727","10.1016/S1473-3099(21)00070-0","Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.","BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 ..g or 6 ..g) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-blind, multicentre, randomised, controlled phase 1 trial on the safety and immunogenicity of three different formulations of BBV152 (3 ..g with Algel-IMDG, 6 ..g with Algel-IMDG, or 6 ..g with Algel) and one Algel-only control (no antigen), with the first dose administered on day 0 and the","2021","03","11","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Ella","Raches","Bharat Biotech, Hyderabad, India",NA
"6","33705636","10.3906/sag-2012-310","CURRENT COMMUNITY TRANSMISSION AND FUTURE PERSPECTIVES ON THE COVID-19 PROCESS.","COVID-19 syndrome due to the SARS-CoV-2 virus is a currently challenging situation ongoing Worldwide. Since the current pandemic of the SARS-CoV-2 virus is a great concern for everybody in the World, the frequently asked question is how and when the COVID-19 process will be concluded. The aim of this paper is to propose hypotheses in order to answer this essential question. As recently demonstrated, SARS-CoV-2 RNAs can be reverse-transcribed and integrated into the human genome. Our main hypothe","2021","03","11","Turk J Med Sci","Turkish journal of medical sciences","COVID-19; Genomic integration; SARS-CoV-2; Virobiota","T..rk","Seyhan",NA,NA
"7","33704435","10.1093/cid/ciab229","Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening.","Several vaccines are now clinically available under emergency use authorization in the United States and have demonstrated efficacy against symptomatic COVID-19. The impact of vaccines on asymptomatic SARS-CoV-2 infection is largely unknown. We conducted a retrospective cohort study of consecutive, asymptomatic adult patients (n = 39,156) within a large United States healthcare system who underwent 48,333 pre-procedural SARS-CoV-2 molecular screening tests between December 17, 2020 and February ","2021","03","11","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Asymptomatic; COVID-19; SARS-CoV-2; vaccination","Tande","Aaron J","Division of Infectious Diseases, Mayo Clinic, Rochester, MN, USA",NA
"8","33704352","10.1001/jama.2021.3645","Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.","Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson &amp; Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses. Twenty-five participants were enrolled from July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was completed on October 3, 2020; fol","2021","03","11","JAMA","JAMA",NA,"Stephenson","Kathryn E","Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts",NA
"9","33693552","10.1093/cid/ciab213","Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines.","COVID-19 vaccine trials provide valuable insight into the safety and efficacy of vaccines, with individually-randomized, placebo-controlled trials being the gold standard in trial design. However, a myriad of variables must be considered as clinical trial data are interpreted and used to guide policy decisions. These variables include factors such as the characteristics of the study population and circulating SARS-CoV-2 strains, the force of infection, the definition and ascertainment of endpoin","2021","03","11","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","COVID-19; SARS-CoV-2; clinical trial; efficacy; vaccine","Rapaka","Rekha R","University of Maryland Center for Vaccine Development and Global Health, University of Maryland School of Medicine",NA
"10","33693529","10.1093/cid/ciab226","Evaluating the Long-Term Efficacy of COVID-19 Vaccines.","Large-scale deployment of safe and durably effective vaccines can curtail the COVID-19 pandemic.1-3 However, the high vaccine efficacy (VE) reported by ongoing phase 3 placebo-controlled clinical trials is based on a median follow-up time of only about two months4-5 and thus does not pertain to long-term efficacy. To evaluate the duration of pro- tection while allowing trial participants timely access to efficacious vaccine, investigators can sequentially cross participants over from the placebo","2021","03","11","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","SARS-CoV-2; booster vaccination; durability of vaccine efficacy; phase 3 trials; severe COVID-19; waning efficacy","Lin","Dan-Yu","Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA",NA
"11","33692215","10.1128/JVI.00194-21","Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19.","Within a year after its emergence, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 100 million people worldwide with a death toll over 2 million. Vaccination remains the best hope to ultimately put this pandemic to an end. Here, using Trimer-Tag technology, we produced both wild-type (WT) and furin site mutant (MT) S-Trimers for COVID-19 vaccine studies. Cryo-EM structures of the WT and MT S-Trimers, determined at 3.2 .. and 2.6 .. respectively, revealed that b","2021","03","11","J Virol","Journal of virology",NA,"Ma","Jiahao","Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, Beijing, China",NA
"12","33691913","","Efficacy and safety of COVID-19 vaccines: a systematic review.","To evaluate systematically the efficacy and safety of COVID-19 vaccines. PubMed, Embase, Cochrane Library, Clinicaltrial.gov, CNKI, Wanfang Data, China Biomedical Literature Service System, and China Clinical Trial Registry were searched for randomized controlled trials of COVID-19 vaccines published up to December 31, 2020. The Cochrane bias risk assessment tool was used to assess the quality of studies. A qualitative analysis was performed on the results of clinical trials. Thirteen randomized","2021","03","12","Zhongguo Dang Dai Er Ke Za Zhi","Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics","Aged; COVID-19; COVID-19 Vaccines; China; Humans; SARS-CoV-2; Vaccines","Xing","Kai","Department of Pediatrics, Renmin Hospital of Wuhan University, Wuhan 430060, China",NA
"13","33691737","10.1186/s12985-021-01525-z","Optimal preparation of SARS-CoV-2 viral transport medium for culture.","The sudden arrival of the COVID-19 pandemic placed significant stresses on supply chains including viral transport medium (VTM). The VTM that was urgently required needed to support viral replication, as well as other routine diagnostic approaches. We describe the preparation and validation testing of VTM for rapidly expanding diagnostic testing, where the capacity of the VTM to preserve viral integrity, for culture, isolation and full sequence analysis, was maintained. VTM was prepared using di","2021","03","14","Virol J","Virology journal","Culture; Diagnosis; SARS-CoV-2; Transport media; VTM","McAuley","Julie","Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, 3000, Australia",NA
"14","33688668","10.1101/2021.02.26.21252483","Mathematical modeling to inform vaccination strategies and testing approaches for COVID-19 in nursing homes.","Nursing home residents and staff were included in the first phase of COVID-19 vaccination in the United States. Because the primary trial endpoint was vaccine efficacy (VE) against symptomatic disease, there are limited data on the extent to which vaccines protect against SARS-CoV-2 infection and the ability to infect others (infectiousness). Assumptions about VE against infection and infectiousness have implications for possible changes to infection prevention guidance for vaccinated population","2021","03","10","medRxiv","medRxiv : the preprint server for health sciences",NA,"Kahn","Rebecca",NA,NA
"15","33688588","10.35772/ghm.2021.01010","COVID-19 vaccines: implementation, limitations and opportunities.","The speed of development and the magnitude of efficacy of recently developed vaccines directed against SARS-CoV-2 has been truly remarkable. This editorial will not summarize the highly publicized and reviewed information about the design and clinical trial results of these vaccines. Rather, I will speculate about several issues regarding i) considerations of the rollout and implementation of the multiple vaccines, ii) the use of the vaccines in ways different from those used in th","2021","03","12","Glob Health Med","Global health &amp; medicine","COVID-19; SARS-CoV-2; vaccine","Richman","Douglas D","University of California San Diego, Distinguished Professor of Pathology and Medicine (Active Emeritus)",NA
"16","33688540","10.4103/jehp.jehp_457_20","Review of investigational drugs for coronavirus disease 2019.","In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became evident in Wuhan, China, and then spread rapidly worldwide. Numerous drugs and vaccines are under clinical trial pipeline for investigation against coronavirus disease 2019 (COVID-19) infection. The aim of this systematic review was to discuss about investigational new as well as repurposed drugs currently under trial for COVID-19 infection. An exhaustive search was carried out for this review article inclu","2021","03","12","J Educ Health Promot","Journal of education and health promotion","Coronavirus; Solidarity trial; coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2","Sharma","Dhruva","Department of Cardiothoracic and Vascular Surgery, SMS Medical College and Attached Hospitals, Jaipur, Rajasthan, India",NA
"17","33688448","10.1007/s40005-021-00520-4","Potential therapeutic and pharmacological strategies for SARS-CoV2.","At the end of 2019, the new Coronavirus disease 2019 (COVID-19) strain causing severe acute respiratory syndrome swept the world. From November 2019 till February 2021, this virus infected nearly 104 million, with more than two million deaths and about 25 million active cases. This has prompted scientists to discover effective drugs to combat this pandemic. Drug repurposing is the magic bullet for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Therefore, several drugs have","2021","03","12","J Pharm Investig","Journal of pharmaceutical investigation","COVID-19; Camostat; Hydroxychloroquine; Indomethacin; Teicoplanin; Tocilizumab","Ghareeb","Doaa A","Biological Screening and Preclinical Trial Laboratory, Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, Egypt",NA
"19","33685502","10.1186/s13063-021-05139-2","Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.","The objective of this trial is to assess whether early antiviral therapy in outpatients with COVID-19 with either favipiravir plus lopinavir/ritonavir, lopinavir/ritonavir alone, or favipiravir alone, is associated with a decrease in viral load of SARS-CoV-2 compared with placebo. FLARE is a phase IIA randomised, double-blind, 2x2 factorial placebo-controlled, interventional trial. This trial is being conducted in the United Kingdom, with Royal Free Hospital, London as the lead site. Participant","2021","03","12","Trials","Trials","COVID-19; antivirals; combination therapy; early treatment; factorial design; favipiravir; lopinavir/ritonavir; placebo-controlled trial; protocol; randomised controlled trial","Brown","Li-An K","UCL Institute of Immunity and Transplantation, Royal Free Hospital, Pond Street, London, NW3 2QG, UK",NA
"20","33683337","10.1182/bloodadvances.2020003880","Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias.","Patients with plasma cell dyscrasias (PCDs) experience an increased burden of influenza, and current practice of single-dose annual influenza vaccination yields suboptimal protective immunity in these patients. Strategies to improve immunity to influenza in these patients are clearly needed. We performed a randomized, double-blind, placebo-controlled clinical trial comparing tandem Fluzone High-Dose influenza vaccination with standard-of-care influenza vaccination. Standard-of-care vaccination w","2021","03","13","Blood Adv","Blood advances",NA,"Branagan","Andrew R","Yale Cancer Center, New Haven, CT",NA
"21","33682615","10.1080/19390211.2021.1890662","Trace Minerals, Vitamins and Nutraceuticals in Prevention and Treatment of COVID-19.","Coronavirus disease 2019 (COVID-19) was first officially diagnosed in the city of Wuhan, China in January 2020. In reality, the disease was identified in December 2019 in the same city where patients began showing symptoms of pneumonia of unidentified origin. Very soon the disease became a global pandemic due to the suppression of information in the country of origin and inadequate testing for the COVID-19 virus. Currently, &gt; 101 million people have been found positive for this virus and &gt;","2021","03","08","J Diet Suppl","Journal of dietary supplements","COVID-19; SARS-CoV-2; cepharanthine; coagulopathy; curcumin; cytokine storm; elderberry; iron transport polyethylene glycol succinate; lactoferrin; metalocomplex curcuminoids; nutraceuticals; trace minerals; vitamins","Srivastava","Ajay","Vets Plus Inc, Menomonie, WI, USA",NA
"22","33681861","10.1016/j.idnow.2021.02.007","Covid-19 vaccines: frequently asked questions and updated answers.","At the end of December 2019, China notified the World Health Organization about a viral pneumonia epidemic soon to be named Covid-19, of which the infectious agent, SARS-CoV-2, was rapidly identified. Less than one year later, published phase 3 clinical trials underlined the effectiveness of vaccines utilizing hitherto unusual technology consisting in injection of the messenger RNA (m-RNA) of a viral protein. In the meantime, numerous clinical trials had failed to identify a maximally effective ","2021","03","08","Infect Dis Now","Infectious diseases now","Covid-19; Review; SARS-CoV-2; Vaccine","Lefebvre","M","Service des Maladies Infectieuses et Tropicales et Centre de Pr..vention des Maladies Infectieuses et Transmissibles, Centre Hospitalo-Universitaire H..tel-Dieu, Inserm CIC1413, Nantes, 1, Place Alexis Ricordeau, 44000 Nantes, France",NA
"23","33681731","10.1016/j.eclinm.2021.100773","Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.","Treatment options for outpatients with COVID-19 could reduce morbidity and prevent SARS-CoV-2 transmission. In this randomized, double-blind, three-arm (1:1:1) placebo-equivalent controlled trial conducted remotely throughout the United States, adult outpatients with laboratory-confirmed SARS-CoV-2 infection were recruited. Participants were randomly assigned to receive hydroxychloroquine (HCQ) (400..mg BID x1day, followed by 200..mg BID x9days) with or without azithromycin (AZ) (500..mg, then 2","2021","03","12","EClinicalMedicine","EClinicalMedicine","Azithromycin; COVID-19; Coronavirus; Early treatment; Hydroxychloroquine; Randomized controlled trial; Remote enrollment; SARS-CoV-2","Johnston","Christine","Division of Allergy and Infectious Diseases, University of Washington, United States",NA
"24","33677827","10.1055/a-1414-5216","Sulodexide in the treatment of patients with early stages of COVID-19: a randomized controlled trial.","Background Sulodexide has pleiotropic properties within the vascular endothelium that can prove beneficial for the treatment of patients with COVID-19. We aimed to evaluate the effect of sulodexide when used in the early clinical stages of COVID-19. Methods In an outpatient setting, we conducted a randomized controlled trial with a parallel-group design. Including patients within three days of clinical onset, who were at a high risk of severe clinical progression due to chronic comorbidities. Pa","2021","03","07","Thromb Haemost","Thrombosis and haemostasis",NA,"Gonzalez Ochoa","Alejandro Jose","IMSS Hospital general de zona No 12, General Surgery, San Luis rio colorado, Mexico",NA
"25","33676782","10.1016/j.vaccine.2020.09.018","Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.","Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development. A replication-incompetent adenoviral vector based on human adenovirus type 26 (Ad26) has been evaluated in several clinical trials. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and features of recombinant viral vector vaccines. This paper reviews features of ","2021","03","12","Vaccine","Vaccine","Benefit/risk; Replication-incompetent Ad26; Safety; Vaccine; Viral vector","Custers","Jerome","Janssen Vaccines &amp",NA
"26","33676266","10.1016/j.ejca.2021.01.033","2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy.","The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious coronavirus disease (COVID-19) has posed a unique challenge to medical staff, patients and their families. Patients with cancer, particularly those with haematologic malignancies, have been identified to be at high risk to develop severe COVID-19. Since publication of our previous guideline on evidence-based management of COVID-19 in patients with cancer, research efforts have c","2021","03","12","Eur J Cancer","European journal of cancer (Oxford, England : 1990)","COVID-19; Cancer; Guideline; Haematological malignancy; SARS-CoV-2; Vaccination","Giesen","Nicola","Department of Haematology and Oncology, Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. Electronic address: nicola.giesen@med.uni-heidelberg","nicola.giesen@med.uni"
"27","33670661","10.3390/vaccines9020172","Vaccine Hesitancy among Italian Patients Recovered from COVID-19 Infection towards Influenza and Sars-Cov-2 Vaccination.","We aimed to assess the attitude towards influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations among coronavirus disease 2019 (COVID-19) recovered patients. We performed a cross-sectional study consisting of a standardized telephone interview carried out between September and November 2020 targeting a cohort of adult in- and out-patients that had recovered from COVID-19 after the first wave (March-May 2020) at Udine Hospital (Italy). Overall, 599 people participa","2021","03","10","Vaccines (Basel)","Vaccines","COVID-19; SARS-CoV-2; influenza; pandemic; vaccination; vaccine hesitancy","Gerussi","Valentina","Infectious Diseases Division, Santa Maria Misericordia University Hospital, 33100 Udine, Italy",NA
"28","33669659","10.3390/vaccines9020175","Assessment of Vaccine Hesitancy to a COVID-19 Vaccine in Cameroonian Adults and Its Global Implication.","Since the outbreak of COVID-19 in December 2019, no global consensus treatment has been developed and generally accepted for the disease. However, eradicating the disease will require a safe and efficacious vaccine. In order to prepare for the eventual development of a safe and efficacious COVID-19 vaccine and to enhance its uptake, it is imperative to assess vaccine hesitancy in Cameroonians. After obtaining ethical clearance from the Institutional Review Board of the University of Buea, a ques","2021","03","10","Vaccines (Basel)","Vaccines","COVID-19 pandemic; Cameroon; clinical trials; vaccine acceptance; vaccine hesitancy","Dinga","Jerome Nyhalah","Biotechnology Unit, Faculty of Science, University of Buea, P.O. Box 63, Buea, Cameroon",NA
"29","33669550","10.3390/v13020317","Viral Vectors for COVID-19 Vaccine Development.","Vaccine development against SARS-CoV-2 has been fierce due to the devastating COVID-19 pandemic and has included all potential approaches for providing the global community with safe and efficient vaccine candidates in the shortest possible timeframe. Viral vectors have played a central role especially using adenovirus-based vectors. Additionally, other viral vectors based on vaccinia viruses, measles viruses, rhabdoviruses, influenza viruses and lentiviruses have been subjected to vaccine devel","2021","03","10","Viruses","Viruses","COVID-19; SARS-CoV-2; adenovirus; approved vaccine; clinical trials; preclinical immunization; vaccines","Lundstrom","Kenneth","PanTherapeutics, CH1095 Lutry, Switzerland",NA
"30","33668923","10.3390/vaccines9030191","The Changing Acceptance of COVID-19 Vaccination in Different Epidemic Phases in China: A Longitudinal Study.","COVID-19 vaccines have been conditionally used in a few countries, including China since December 2020. The present study aimed to examine whether the acceptance of COVID-19 vaccination changed in different COVID-19 epidemic phases in China. Two consecutive surveys were conducted among Chinese adults in March (n = 2058) (severe epidemic phase) and November-December (n = 2013) (well-contained phase, right before the COVID-19 vaccine was conditionally approved) 2020, and 791 responde","2021","03","10","Vaccines (Basel)","Vaccines","COVID-19; China; change; phase; vaccine acceptance","Wang","Jiahao","School of Public Health, Peking University, Beijing 100083, China",NA
"31","33666240","10.1002/jmv.26922","Vaccination hesitancy and the &quot;myth&quot; on mRNA-based vaccines in Italy in the COVID-19 era: does urgency meet major safety criteria?","COVID-19 vaccination campaign in Italy has started with a huge perplexity about vaccine efficacy, vaccine-borne adverse effects and vaccine clinical trial studies. In this commentary I tried to elucidate these issues, which represent a fundamental topic to be thoroughly addressed in COVID-19 pandemic. This article is protected by copyright. All rights reserved.","2021","03","05","J Med Virol","Journal of medical virology","Administrative law &lt; Social Science; Coronavirus &lt; Virus classification; Political science &lt; Social Science; Public policy &lt; Social Science","Chirumbolo","Salvatore","Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy",NA
"32","33666206","10.1039/d0bm02077j","SARS-CoV-2 and tissue damage: current insights and biomaterial-based therapeutic strategies.","The effect of SARS-CoV-2 infection on humanity has gained worldwide attention and importance due to the rapid transmission, lack of treatment options and high mortality rate of the virus. While scientists across the world are searching for vaccines/drugs that can control the spread of the virus and/or reduce the risks associated with infection, patients infected with SARS-CoV-2 have been reported to have tissue/organ damage. With most tissues/organs having limited regenerative potential, interve","2021","03","05","Biomater Sci","Biomaterials science",NA,"Roy","Himadri Shekhar","Department of Biological Science, Institute of Nanoscience and Technology (INST), Habitat Centre, Sector 64, Phase 10, Mohali-160062, Punjab, India. deepa.ghosh@inst.ac","deepa.ghosh@inst.ac.in"
"33","33664546","10.18773/austprescr.2020.084","COVID-19 vaccines - are we there yet?","The novel coronavirus SARS-CoV-2, the cause of the COVID-19 pandemic, is a highly infectious human respiratory pathogen to which the global population had no prior immunity. The virus will likely continue to cause significant morbidity until there is a broadly effective vaccine As of mid-December 2020, more than 200 COVID-19 vaccine candidates are in development and 11 have entered phase III clinical trials globally. All generate immunity to the viral spike glycoprotein Three vaccine candidates ","2021","03","06","Aust Prescr","Australian prescriber","COVID-19; clinical trials; coronavirus; immunisation; vaccine safety","McIntyre","Peter","National Centre for Immunisation Research and Surveillance (NCIRS)",NA
"34","33664123","10.1136/bmjresp-2020-000857","Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study.","Recent evidence suggests that influenza vaccination may offer protection against COVID-19 severity. Our aim was to quantify the association between influenza vaccination status and risk of hospitalisation or all-cause mortality in people diagnosed with COVID-19. A retrospective cohort study using routinely collected health records from patients registered to a General Practitioner (GP) practice in South West England within the Electronic Care and Health Information Analytics database. The cohort","2021","03","10","BMJ Open Respir Res","BMJ open respiratory research","COVID-19; infection control; innate immunity; respiratory infection","Wilcox","Christopher R","Primary Care Research Centre, University of Southampton, Southampton, UK christopher.wilcox@doctors.org","christopher.wilcox@doctors.org.uk"
"35","33664082","10.1136/bmj.n541","Avoiding exploitation in multinational covid-19 vaccine trials.",NA,"2021","03","10","BMJ","BMJ (Clinical research ed.)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Health Services Accessibility; Humans; Patient Selection","Iyer","Alexander A","Department of Bioethics, National Institutes of Health Clinical Center, Bethesda, MD, USA",NA
"36","33662986","10.24875/BMHIM.20000217","Development of SARS-CoV-2 vaccines.","The coronavirus disease 2019 (COVID-19) pandemic has posed significant challenges globally. Continuous transmission of the virus is mostly due to insufficient infection control measures and a lack of vaccines. Therefore, this review aimed to identify and describe possible vaccines for the prevention of COVID-19. A systematic review of the scientific literature was performed through electronic searches of the main databases to identify published reports or studies on vaccines under development ag","2021","03","10","Bol Med Hosp Infant Mex","Boletin medico del Hospital Infantil de Mexico","Biotechnology; Biotecnolog..a; COVID-19; Coronavirus disease 2019; Infecci..n; Infection; Prevenci..n; Prevention; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccine; Vacuna","Barajas-Nava","Leticia A","Unidad de Investigaci..n de Medicina Basada en Evidencias, Hospital Infantil de M..xico Federico G..mez, Mexico City, Mexico",NA
"37","33662102","10.1001/jama.2021.3071","Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.","Ivermectin is widely prescribed as a potential treatment for COVID-19 despite uncertainty about its clinical benefit. To determine whether ivermectin is an efficacious treatment for mild COVID-19. Double-blind, randomized trial conducted at a single site in Cali, Colombia. Potential study participants were identified by simple random sampling from the state's health department electronic database of patients with symptomatic, laboratory-confirmed COVID-19 during the study period. A total of 476 ","2021","03","04","JAMA","JAMA",NA,"L..pez-Medina","Eduardo","Centro de Estudios en Infectolog..a Pedi..trica, Cali, Colombia",NA
"38","33657648","10.1111/all.14794","Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation.","Following the emergency use authorization of the mRNA-1273 vaccine on the 18<sup>th</sup> of December2020,two mRNAvaccinesare in current use for the prevention of coronavirus disease 2019 (COVID-19). For both mRNA vaccines, the phase IIIpivotal trials excluded individuals with a history of allergy tovaccine components.Immediately after the initiation of vaccination in the United Kingdom, Canada, and the US, anaphylactic reactions were reported. While the culprit trigger requires investigation, i","2021","03","03","Allergy","Allergy",NA,"Klimek","Ludger","Center for Rhinology and Allergology, Wiesbaden, Germany",NA
"39","33655830","10.2174/1389557521666210224161950","Treatment approaches for COVID-19: A critical review.","Coronavirus disease 2019 (COVID-19) outbreak was declared as an emergency global public health concern on 30 January 2020. This novel coronavirus (SARS-CoV-2) outbreak was first identified in Wuhan city, China; which soon affected around 185 countries and territories all over the world through various transmission mechanisms. Having found no permanent cure to date, this pandemic threatens humanity for its very existence. In the light of rising menace, this review aims at providing collective and","2021","03","03","Mini Rev Med Chem","Mini reviews in medicinal chemistry","Antibiotics; Antimalarial drugs; Immune therapy; Plasma therapy. ; SARS-CoV-2; Vaccines","Sodum","Nalini","Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal-576104, Karnataka. India",NA
"40","33655276","10.1101/2021.02.25.21252415","Interpreting vaccine efficacy trial results for infection and transmission.","Randomized controlled trials (RCTs) have shown high efficacy of multiple vaccines against SARS-CoV-2 disease (COVID-19), but evidence remains scarce about vaccines' efficacy against infection with, and ability to transmit, the virus. We describe an approach to estimate these vaccines' effects on viral positivity, a prevalence measure which under reasonable assumptions forms a lower bound on efficacy against transmission. Specifically, we recommend separate analysis of positive tests triggered by","2021","03","03","medRxiv","medRxiv : the preprint server for health sciences",NA,"Lipsitch","Marc",NA,NA
"41","33655271","10.1101/2021.02.25.21252402","Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake.","Racial and ethnic minorities have been disproportionately impacted by COVID-19. In the initial phase of population-based vaccination in the United States (U.S.) and United Kingdom (U.K.), vaccine hesitancy and limited access may result in disparities in uptake. We performed a cohort study among U.S. and U.K. participants in the smartphone-based COVID Symptom Study (March 24, 2020-February 16, 2021). We used logistic regression to estimate odds ratios (ORs) of COVID-19 vaccine hesitancy (unsure/n","2021","03","10","medRxiv","medRxiv : the preprint server for health sciences",NA,"Nguyen","Long H",NA,NA
"42","33654090","10.1038/s41467-021-21639-w","Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.","The COVID-19 pandemic is a global health crisis that poses a great challenge to the public health system of affected countries. Safe and effective vaccines are needed to overcome this crisis. Here, we develop and assess the protective efficacy and immunogenicity of an inactivated SARS-CoV-2 vaccine in rhesus macaques. Twenty macaques were divided into four groups of five animals each. One group was administered a placebo, while three groups were immunized with three different vaccine candidates ","2021","03","11","Nat Commun","Nature communications","Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19 Vaccines; Enzyme-Linked Immunosorbent Assay; Female; Immunohistochemistry; Lymphocytes; Macaca mulatta; Male; Pneumonia; SARS-CoV-2","Yadav","Pragya D","Indian Council of Medical Research-National Institute of Virology, Pune, 411021, Maharashtra, India",NA
"43","33652582","10.3390/medicina57030199","Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials.","Relative risk reduction and absolute risk reduction measures in the evaluation of clinical trial data are poorly understood by health professionals and the public. The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects the interpretation of vaccine efficacy. The present article uses clinical epidemiologic tools to critically appraise reports of efficacy in Pfzier/BioNTech and Moderna COVID-19 mRNA vaccine clinical trial","2021","03","08","Medicina (Kaunas)","Medicina (Kaunas, Lithuania)","COVID-19 vaccine; absolute risk reduction; clinical epidemiology; critical appraisal; evidence-based medicine; mRNA vaccine; number needed to vaccinate; outcome reporting bias; relative risk reduction; vaccine efficacy; Bias; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Numbers Needed To Treat; RNA, Viral; Risk; SARS-CoV-2; Treatment Outcome","Brown","Ronald B","School of Public Health and Health Systems, University of Waterloo, Waterloo, ON N2L3G1, Canada",NA
"44","33651967","10.1080/21645515.2021.1880210","..-glucans: wide-spectrum immune-balancing food-supplement-based enteric (..-WIFE) vaccine adjuvant approach to COVID-19.","Conventional vaccines to combat COVID-19 through different approaches are at various stages of development. The complexity of COVID-19 such as the potential mutations of the virus leading to antigenic drift and the uncertainty on the duration of the immunity induced by the vaccine have hampered the efforts to control the COVID-19 pandemic. Thus, we suggest an alternative interim treatment strategy based on biological response modifier glucans such as the Aureobasidium pullulans AFO-202-de","2021","03","10","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","AFO-202 Beta glucan; Covid-19; immune enhancement; trained Immunity; vaccine adjuvant","Ikewaki","Nobunao","Department of Medical Life Science, Kyushu University of Health and Welfare, Nobeoka, Japan",NA
"45","33647606","10.1016/j.mehy.2021.110537","Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C.","As the COVID-19 pandemic continues, researchers seek to identify efficacious treatments. Current approaches to COVID-19 therapeutics focus on antiviral agents, convalescent plasma, monoclonal antibodies, immunomodulators and more traditional therapies such as steroids [1-6]. Reversing disturbances in coagulation has also been identified as a priority area for candidate therapies, such as through the Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 adaptive clinical trial (ACTIV-4) ","2021","03","12","Med Hypotheses","Medical hypotheses","Activated protein C; COVID-19; COVID-19 therapeutics","Pestka","Steven B","Tufts University School of Medicine, Department of Medicine, Newton-Wellesley Hospital, 2014 Washington Street, Newton, MA 02462, USA. Electronic address: spestka@partners","spestka@partners.org"
"46","33646996","","FDA authorizes Pfizer-BioNTech COVID-19 vaccine.",NA,"2021","03","09","Med Lett Drugs Ther","The Medical letter on drugs and therapeutics","COVID-19; Vaccines; adverse effects; dosage; efficacy; lactation; pregnancy; safety; COVID-19; COVID-19 Vaccines; Drug Approval; Fatigue; Headache; Humans; Randomized Controlled Trials as Topic; United States",NA,NA,NA,NA
"47","33644298","10.1016/j.imu.2021.100540","COVIDC: An expert system to diagnose COVID-19 and predict its severity using chest CT scans: Application in radiology.","Early diagnosis of Coronavirus disease 2019 (COVID-19) is significantly important, especially in the absence or inadequate provision of a specific vaccine, to stop the surge of this lethal infection by advising quarantine. This diagnosis is challenging as most of the patients having COVID-19 infection stay asymptomatic while others showing symptoms are hard to distinguish from patients having different respiratory infections such as severe flu and Pneumonia. Due to cost and time-consuming wet-la","2021","03","05","Inform Med Unlocked","Informatics in medicine unlocked","COVID-19; CT imaging; Early diagnosis; Expert system; Pandemic; Radiology; SARS-COV-2","Abbasi","Wajid Arshad","Computational Biology and Data Analysis Lab., Department of Computer Science &amp",NA
"48","33643776","10.1007/s40629-020-00160-4","Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA).","Two employees of the National Health Service (NHS) in England developed severe allergic reactions following administration of BNT162b2 vaccine against COVID-19 (coronavirus disease 2019). The British SmPC for the BNT162b2 vaccine already includes reference to a..contraindication for use in individuals who have had an allergic reaction to the vaccine or any of its components. As a..precautionary measure, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued interim guidance to","2021","03","03","Allergo J Int","Allergo journal international","Anaphylaxis; BNT162b2; Severe allergic reactions; Vaccines; mRNA","Klimek","Ludger","Center for Rhinology and Allergology Wiesbaden, Wiesbaden, Germany",NA
"49","33643421","10.7573/dic.2020-12-2","The race to a COVID-19 vaccine: opportunities and challenges in development and distribution.","The unprecedented toll of severe acute respiratory syndrome coronavirus 2, the virus responsible for coronavirus 2019 disease (COVID-19), jumpstarted the race towards the development and distribution of effective treatment and prevention options. With an urgent need to slow viral transmission, lessen disease severity, and reduce mortality, biopharmaceutical companies rapidly began investigating potential COVID-19 vaccinations. While typical vaccine development can take upwards of 10-15 years, CO","2021","03","03","Drugs Context","Drugs in context","COVID-19; SARS-CoV-2; coronavirus; vaccine","Burgos","Rodrigo M","University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA",NA
"50","33640286","10.1016/j.zefq.2021.01.007","[Vaccination against influenza: International inventory and perspectives for Germany].","The current SARS-CoV-2 pandemic requires high influenza vaccination rates for the chronically ill in order to avoid additional strain on the health care system. Despite clear evidence of the safety and effectiveness of influenza vaccination, vaccination coverage has internationally remained at inadequate levels in recent years. The general practitioner is of central importance for the care of this population. Therefore, the aim of this systematic review was to evaluate various measures in genera","2021","03","05","Z Evid Fortbild Qual Gesundhwes","Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen","Chronic disease; Chronisch Kranke; Gesundheitssystem; Health care system; Impfung; Influenza; Review; Vaccination; ..bersichtsarbeit","Brombacher","Felix","Institut f..r Allgemeinmedizin, Klinikum der Universit..t M..nchen, Ludwig-Maximilians-Universit..t M..nchen, Deutschland",NA
"51","33640145","10.1016/j.vaccine.2021.01.054","Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition &amp; guidelines for data collection, analysis, and presentation of immunization safety data.","This is a Brighton Collaboration Case Definition of the term &quot;Multisystem Inflammatory Syndrome in Children and Adults (MIS-C/A)&quot; to be utilized in the evaluation of adverse events following immunization. The case definition was developed by topic experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2. The format of the Brighton Collaboration was followed, including an exhaustive review of the liter","2021","03","13","Vaccine","Vaccine","Adults; Adverse event; Case definition; Children; Guidelines; Immunization; MIS-A; MIS-C; Multisystem inflammatory syndrome","Vogel","Tiphanie P","Department of Pediatrics, Section of Rheumatology, Baylor College of Medicine, Houston, TX, USA","coordinator@taskforce.org"
"52","33640052","10.1016/S0140-6736(21)00508-0","Peruvian COVID-19 vaccine scandal spreads.",NA,"2021","03","10","Lancet","Lancet (London, England)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Government Employees; Humans; Leadership; Pandemics; Peru; Politics; SARS-CoV-2","Chauvin","Lucien",NA,NA
"53","33639625","10.18502/ijaai.v20i1.5417","Relationship between Bacillus Calmette Guerin Vaccination Policy and Coronavirus Disease-2019 (COVID-19) Incidence.","Bacillus Calmette Guerin (BCG) was designed for protecting children against tuberculosis. Also, it can protect against other infectious diseases through the induction of trained immunity. Due to its heterologous protective effects, the BCG vaccine has been proposed as atreatment option for coronavirus disease-2019 (COVID-19). Epidemiological studies have found that countries without BCG vaccination policy have experienced higher mortality rates related toCOVID-19 infection than those with BCG va","2021","03","10","Iran J Allergy Asthma Immunol","Iranian journal of allergy, asthma, and immunology","COVID-19; Mycobacterium bovis; BCG Vaccine; COVID-19; Child; Humans; Incidence; Iran; Mycobacterium bovis; Pandemics; Policy; SARS-CoV-2; Tuberculosis; Vaccination","Alyasin","Soheila","Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran AND Department of Allergy and Clinical Immunology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. alyasins@sums.ac","alyasins@sums.ac.ir"
"54","33639165","10.1016/j.jbc.2021.100470","Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and Influenza virus.","The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health. Vaccines are ideal solutions to prevent infection, but treatments are also needed for those who have contracted the virus to limit negative outcomes, when vaccines are not applicable. Viruses must cross host cell membranes during their lifecycle, creating a dependency on processes involving membrane dynamics. Thus, in this study we examined whether the synthe","2021","03","02","J Biol Chem","The Journal of biological chemistry","COVID-19; GlucosylCeramide Synthase; Glucosylceramide; SARS-CoV-2; Sphingolipids; antiviral drugs","Vitner","Einat B","Departments of Infectious diseases, Israel institute for Biological Research, Ness-Ziona, 7410000, Israel. Electronic address: einatv@iibr.gov","einatv@iibr.gov.il"
"55","33637387","10.1016/j.vaccine.2021.01.055","Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.","This is a Brighton Collaboration Case Definition of the term &quot;Vaccine Associated Enhanced Disease&quot; to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a con","2021","03","02","Vaccine","Vaccine","Adverse event; Case definition; Enhanced disease; Guidelines; Immunization; Respiratory; Systemic disease; Vaccine","Munoz","Flor M","Departments of Pediatrics, Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. Electronic address: florm@bcm","florm@bcm.edu"
"56","33635275","10.2196/22483","Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic.","The COVID-19 pandemic presents a great public health challenge worldwide, especially given the urgent need to identify effective drugs and develop a vaccine in a short period of time. Globally, several drugs and vaccine candidates are in clinical trials. However, because these drugs and vaccines are still being tested, there is still no definition of which ones will succeed. This study aimed to assess the opinions of over 1000 virus researchers with knowledge on the prevention and treatment of c","2021","03","03","JMIR Public Health Surveill","JMIR public health and surveillance","COVID-19; SARS-CoV-2; clinical trial; drug; public health; survey; treatment; vaccine; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Cross-Sectional Studies; Expert Testimony; Global Health; Humans; Pandemics; Research Personnel","Cabral","Bernardo Pereira","Faculty of Economics, Federal University of Bahia, Salvador, Brazil",NA
"57","33634346","10.1007/s10654-021-00729-5","External validity of phase III trials on vaccines against SARS-CoV-2 to a middle-aged and elderly Western European population.","Initial results from various phase-III trials on vaccines against SARS-CoV-2 are promising. For proper translation of these results to clinical guidelines, it is essential to determine how well the general population is reflected in the study populations of these trials. This study was conducted among 7162 participants (age-range: 51-106..years; 58% women) from the Rotterdam Study. We quantified the proportion of participants that would be eligible for the nine ongoing phase-III trials. We furth","2021","02","28","Eur J Epidemiol","European journal of epidemiology","Epidemiology; External validity; Generalizability; Phase III trials; SARS-CoV-2; Vaccines","Terzikhan","Natalie","Department of Epidemiology, Erasmus University Medical Center, Wytemaweg 80, 3015 CN, Rotterdam, the Netherlands",NA
"58","33632828","10.1126/science.371.6532.874","Vaccine trials ramp up in children and adolescents.",NA,"2021","03","09","Science","Science (New York, N.Y.)","Adolescent; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Child; Clinical Trials as Topic; Humans; SARS-CoV-2; Vaccination","Couzin-Frankel","Jennifer",NA,NA
"59","33632286","10.1186/s13063-021-05138-3","Traditional Chinese medicine auricular point acupressure for the relief of pain, fatigue, and gastrointestinal adverse reactions after the injection of novel coronavirus-19 vaccines: a structured summary of a study protocol for a multicentre, three-arm, single-blind, prospective randomized controlled trial.","To investigate if traditional Chinese medicine (TCM) auricular point acupressure (APA) can alleviate and (or) reduce the pain (including injection site pain, headache, other muscle and joint pain), fatigue, and gastrointestinal adverse reactions (including nausea, vomiting, diarrhea), after the injection of novel coronavirus-19 vaccines (NCVs). The study is designed as a multicentre, parallel-group, three-arm, single-blind, prospective, randomized (1:1:1 ratio) study. More than 360 participants ","2021","03","03","Trials","Trials","Auricular point; Acupressure; Adverse reactions; COVID-19 vaccines; COVID-19; Randomised controlled trial; Traditional Chinese medicine; protocol; Acupressure; Acupuncture Points; Adolescent; Adult; COVID-19 Vaccines; China; Ear Auricle; Fatigue; Female; Gastrointestinal Diseases; Humans; Injection Site Reaction; Injections, Intramuscular; Male; Middle Aged; Multicenter Studies as Topic; Pain; Prospective Studies; Randomized Controlled Trials as Topic; Single-Blind Method; Time Factors; Treatment Outcome; Vaccination; Young Adult","Fu","Qinwei","Hospital of Chengdu university of Traditional Chinese Medicine, Chengdu university of Traditional Chinese Medicine, Chengdu, 610075, China",NA
"60","33628952","10.15167/2421-4248/jpmh2020.61.4.1814","Drive-through vaccinations prove successful in immunizing mountain communities against tick-borne encephalitis during the COVID-19 pandemic.","In March 2020, the COVID-19 pandemic disrupted most of the routine outpatient activities in Italian hospitals and Prevention Departments, including those vaccinations which were not urgent and/or scheduled for children aged 0-6 years. Since June 2020, when the pandemic entered a milder phase, in the alpine Province of Belluno (Veneto, North-Eastern Italy), 12,152 doses of vaccine against tick-borne encephalitis have been administered by means of the innovative &quot;drive-through&quot; modality.","2021","03","04","J Prev Med Hyg","Journal of preventive medicine and hygiene","COVID-19; Drive-through; TBE vaccine; Ambulatory Care Facilities; COVID-19; Child; Child Welfare; Encephalitis, Tick-Borne; Humans; Italy; Vaccination; Viral Vaccines","DE Polo","Anna","University of Padova, School of Specialization in Hygiene and Public Health, Padova, Italy",NA
"61","33628442","10.1002/cti2.1241","Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant.","The emergence of a SARS-CoV-2 variant with a point mutation in the spike (S) protein, D614G, has taken precedence over the original Wuhan isolate by May 2020. With an increased infection and transmission rate, it is imperative to determine whether antibodies induced against the D614 isolate may cross-neutralise against the G614 variant. Antibody profiling against the SARS-CoV-2 S protein of the D614 variant by flow cytometry and assessment of neutralising antibody titres using pseudotyped lentiv","2021","02","26","Clin Transl Immunology","Clinical &amp; translational immunology","COVID...19; D614G variant; SARS...CoV...2; clade; cross...reactivity; neutralising antibodies","Lee","Cheryl Yi-Pin","ASTAR Infectious Diseases Labs Agency for Science, Technology and Research (A*STAR) Singapore",NA
"62","33627824","10.1038/s41390-021-01402-z","SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.","As the nation implements SARS-CoV-2 vaccination in adults at an unprecedented scale, it is now essential to focus on the prospect of SARS-CoV-2 vaccinations in pediatric populations. To date, no children younger than 12 years have been enrolled in clinical trials. Key challenges and knowledge gaps that must be addressed include (1) rationale for vaccines in children, (2) possible effects of immune maturation during childhood, (3) ethical concerns, (4) unique needs of children with developmental ","2021","02","28","Pediatr Res","Pediatric research",NA,"Cooper","Dan M","Institute for Clinical and Translational Science, UC Irvine, Irvine, CA, USA",NA
"63","33627440","10.1136/rmdopen-2021-001594","Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases.","In view of the COVID-19 pandemic, there is an unmet clinical need for the guidelines on vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD). This position paper summarises the current data on COVID-19 infection in patients with AIIRD and development of vaccines against COVID-19, discusses the aspects of efficacy and safety of vaccination, and proposes preliminary considerations on vaccination against COVID-19 in patients with AIIRD, mainly based on the expert opinion ","2021","03","04","RMD Open","RMD open","COVID-19; autoimmune diseases; vaccination; Adolescent; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Middle Aged; Patient Safety; Practice Guidelines as Topic; Rheumatic Diseases; SARS-CoV-2; Young Adult","Furer","Victoria","Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel furer.rheum@gmail","furer.rheum@gmail.com"
"64","33627357","10.1136/bmj.n522","Optimal dosing interval for covid-19 vaccines: we need clinical trial evidence and to consider past infection.",NA,"2021","03","04","BMJ","BMJ (Clinical research ed.)","COVID-19; COVID-19 Vaccines; Humans; SARS-CoV-2","M..ller-Sedgwick","Ulrich","Barnet, Enfield, and Haringey Mental Health NHS Trust, London N15 3TH, UK",NA
"65","33627051","10.1080/16549716.2021.1892309","Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials.","Coronavirus disease 2019 (COVID-19) mortality and morbidity have been shown to increase with deprivation and impact non-White ethnicities more severely. Despite the extra risk Black, Asian and Minority Ethnicity (BAME) groups face in the pandemic, our current medical research system seems to prioritise innovation aimed at people of European descent. We found significant difficulties in assessing baseline demographics in clinical trials for COVID-19 vaccines, displaying a lack of transparency in ","2021","03","08","Glob Health Action","Global health action","Covid-19; clinical trials; ethnic minorities; health equity; vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Communicable Disease Control; Ethnic Groups; Female; Health Equity; Humans; Male; Minority Groups; Pandemics; SARS-CoV-2","Pepperrell","Toby","School of Medicine, Imperial College London, London, UK",NA
"66","33626250","10.1056/NEJMoa2101765","BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.","As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. In this study, data from Israel's largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine. All persons who were newly vaccinated during the period from December 20, 2020, to February 1, 2021, were matched to unvaccinated controls in a 1:1","2021","02","24","N Engl J Med","The New England journal of medicine",NA,"Dagan","Noa","From the Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv (N.D., N.B., E.K., O.M., S.P., M.A.K., R.D.B.), and the School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Be'er Sheva (O.M., M.A.K., R.D.B.) - both in Israel",NA
"67","33625817","10.1503/cjs.002921","Lessons (so far) from the COVID-19 pandemic.",NA,"2021","03","08","Can J Surg","Canadian journal of surgery. Journal canadien de chirurgie","COVID-19; COVID-19 Vaccines; Canada; Clinical Trials as Topic; Cooperative Behavior; Humans; Manufacturing and Industrial Facilities; Pandemics; Vaccination","Harvey","Edward J","From the Department of Surgery, McGill University, Montreal, Que",NA
"68","33623865","10.1007/s42399-021-00827-1","The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2.","Convalescent plasma therapy has been used successfully in the past to treat respiratory infections. In SARS-CoV-2, there was initially strong evidence in favor of convalescent plasma therapy from a large observational study but the evidence from recent randomized controlled trials has been mixed. However, two of those studies provided convalescent plasma therapy on average 8 days after diagnosis despite earlier data proving that the therapy is most effective when given within 3 days of diagnosis","2021","02","25","SN Compr Clin Med","SN comprehensive clinical medicine","Ambulatory therapy; Convalescent plasma; SARS-CoV-2","Fisher","David L","Kaplan Medical Center, Derech Pasternak 1, 76100 Rehovot, Israel",NA
"69","33623151","10.1038/d41586-021-00409-0","Why COVID vaccines are so difficult to compare.",NA,"2021","03","05","Nature","Nature","Immunology; Infection; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Developing Countries; Humans; Program Evaluation; SARS-CoV-2; South Africa; Time Factors; Uncertainty","Ledford","Heidi",NA,NA
"70","33622695","10.1136/bmj.n271","Behind the scenes of the Pfizer BioNTech covid-19 vaccine trial.",NA,"2021","02","25","BMJ","BMJ (Clinical research ed.)",NA,"Silberner","Joanne","The BMJ",NA
"71","33619489","10.1101/2021.02.15.431215","Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.","There is an urgent need to understand the nature of immune responses generated against SARS-CoV-2, to better inform risk-mitigation strategies for people living with HIV (PLWH). Although not all PLWH are considered immunosuppressed, residual cellular immune deficiency and ongoing inflammation could influence COVID-19 disease severity, the evolution and durability of protective memory responses. Here, we performed an integrated analysis, characterizing the nature, breadth and magnitude of SARS-Co","2021","02","28","bioRxiv","bioRxiv : the preprint server for biology",NA,"Alrubayyi","Aljawharah",NA,NA
"72","33619260","10.1038/s41541-021-00292-w","SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.","The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and causes COVID-19 disease. The newly sequenced virus appears to originate in China and rapidly spread throughout the world, becoming a pandemic that, until January 5th, 2021, has caused more than 1,866,000 deaths. Hence, laboratories worldwide are developing an effective vaccine against this disease, which will be essential to reduce morbidity and mortality. Currently, there more than 64 vaccine candidates, most ","2021","03","06","NPJ Vaccines","NPJ vaccines",NA,"Kyriakidis","Nikolaos C","One Health Research Group, Universidad de Las Am..ricas (UDLA), Quito, Ecuador. nickyriakidis82@yahoo","nickyriakidis82@yahoo.gr"
"73","33619178","10.1073/pnas.2021726118","Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance.","Although a safe and effective vaccine holds the greatest promise for resolving the COVID-19 pandemic, hesitancy to accept vaccines remains common. To explore vaccine acceptance decisions, we conducted a national survey of 1,000 people from all US states in August of 2020 and a replication in December of 2020. Using a 3 .. 3 .. 3 factorial experimental design, we estimated the impact of three factors: probability of 1) protection against COVID-19, 2) minor side effects, and 3) a serious adverse r","2021","03","04","Proc Natl Acad Sci U S A","Proceedings of the National Academy of Sciences of the United States of America","COVID-19; conjoint analysis; decision analysis; vaccine acceptance; Adolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Female; Health Surveys; Humans; Male; Middle Aged; Patient Acceptance of Health Care; Politics; Random Allocation; United States; Young Adult","Kaplan","Robert M","Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, CA 94305 bob.kaplan@stanford","bob.kaplan@stanford.edu"
"74","33619170","10.1136/bmj.n188","Vaccines for older adults.","The proportion of the global population aged 65 and older is rapidly increasing. Infections in this age group, most recently with SARS-CoV-2, cause substantial morbidity and mortality. Major improvements have been made in vaccines for older people, either through the addition of novel adjuvants-as in the new recombinant zoster vaccine and an adjuvanted influenza vaccine-or by increasing antigen concentration, as in influenza vaccines. In this article we review improvements in immunization for th","2021","03","03","BMJ","BMJ (Clinical research ed.)","Adjuvants, Immunologic; Age Factors; Aged; Aged, 80 and over; Animals; COVID-19; Female; Herpes Zoster Vaccine; Humans; Immunosenescence; Influenza Vaccines; Male; Mice; Middle Aged; Pneumococcal Vaccines; Randomized Controlled Trials as Topic; SARS-CoV-2","Cunningham","Anthony L","Centre for Virus Research, The Westmead Institute for Medical Research, Faculty of Medicine and Health, University of Sydney, Australia tony.cunningham@sydney.edu","tony.cunningham@sydney.edu.au"
"75","33618668","10.1186/s12866-021-02107-3","Identification and functional analysis of the SARS-COV-2 nucleocapsid protein.","A severe form of pneumonia, named coronavirus disease 2019 (COVID-19) by the World Health Organization is widespread on the whole world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was proved to be the main agent of COVID-19. In the present study, we conducted an in depth analysis of the SARS-COV-2 nucleocapsid to identify potential targets that may allow identification of therapeutic targets. The SARS-COV-2...N protein subcellular localization and physicochemical property w","2021","03","02","BMC Microbiol","BMC microbiology","Nucleocapsid protein (N protein); Phosphorylation; SARS-COV-2; Structure; Amino Acid Sequence; COVID-19; Genome, Viral; HCT116 Cells; Humans; Molecular Sequence Data; Nucleocapsid Proteins; Phosphorylation; Reproducibility of Results; SARS-CoV-2; Viral Vaccines","Gao","Tianyi","Department of clinical Laboratory, Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing, 210006, Jiangsu, China",NA
"77","33617777","10.1016/S0140-6736(21)00432-3","Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.","The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exp","2021","03","10","Lancet","Lancet (London, England)",NA,"Voysey","Merryn","Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK",NA
"78","33616486","10.1080/15265161.2020.1870768","Equitable Access to Research Benefits: Considerations for COVID-19 Vaccine Development and Clinical Trial Crossover.",NA,"2021","02","25","Am J Bioeth","The American journal of bioethics : AJOB","COVID-19; COVID-19 Vaccines; Humans; Pandemics; Racism; SARS-CoV-2","Zaidi","Danish","Yale University School of Medicine",NA
"79","33615193","10.1021/acsptsci.1c00015","Glycosylation of SARS-CoV-2 Steers Evolutionary Outcomes in the Postvaccination Phase.","There is a need to assess evolutionary outcomes for SARS-CoV-2 in the postvaccination phase. The role of virus glycosylation in deterring the development of vaccine resistance is weighed against the epitopes of extant vaccines and the modulation of induced immune surveillance on antigens containing glycosylation sites.","2021","02","23","ACS Pharmacol Transl Sci","ACS pharmacology &amp; translational science",NA,"Fern..ndez","Ariel","Daruma Institute for AI in Pharmaceutical Research, AF Innovation Pharma Consultancy, 4000 Pemberton Court, Winston-Salem, North Carolina 27106, United States",NA
"80","33615191","10.1021/acsptsci.0c00220","COVID-19 Evolution in the Post-Vaccination Phase: Endemic or Extinct?","This piece addresses the urge to assess the evolutionary fate of SARS-CoV-2 in a post-vaccination phase. The possibilities of COVID-19 becoming endemic or extinct are weighed against verifiable properties of extant vaccines and observed genetic trends already apparent under the mild selection pressure exerted almost exclusively by social rules.","2021","02","23","ACS Pharmacol Transl Sci","ACS pharmacology &amp; translational science",NA,"Fern..ndez","Ariel","Daruma Institute for AI in Pharmaceutical Research, AF Innovation Pharma Consultancy, 4000 Pemberton Court, Winston-Salem, North Carolina 27106, United States",NA
"81","33612319","10.1016/j.revmed.2021.02.001","[In subjects 16 years of age and older, is messenger RNA vaccine BNT162b2 against COVID-19 effective and safe?]",NA,"2021","03","11","Rev Med Interne","La Revue de medecine interne","Adolescent; Adult; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Immunotherapy, Active; Male; Middle Aged; Pandemics; Patient Safety; RNA, Messenger; SARS-CoV-2; Treatment Outcome; Young Adult","Lanthier","L","D..partement de m..decine sp..cialis.., service de m..decine interne g..n..rale, Universit.. de Sherbrooke, Sherbrooke, QC, Canada. Electronic address: luc.lanthier@usherbrooke","luc.lanthier@usherbrooke.ca"
"82","33608249","10.1126/sciadv.abe8065","Immunogenicity of clinically relevant SARS-CoV-2 vaccines in non-human primates and humans.","Multiple preventive vaccines are being developed to counter the COVID-19 pandemic. The leading candidates have now been evaluated in non-human primates (NHPs) and human Phase 1 and/or Phase 2 clinical trials. Several vaccines have already advanced into Phase 3 efficacy trials, while others will do so before the end of 2020. Here, we summarize what is known of the antibody and T-cell immunogenicity of these vaccines in NHPs and humans. To the extent possible, we compare how the vaccines have perf","2021","02","20","Sci Adv","Science advances",NA,"Klasse","P J","Department of Microbiology and Immunology",NA
"83","33606782","10.1371/journal.pone.0246941","Attitudes, current behaviours and barriers to public health measures that reduce COVID-19 transmission: A qualitative study to inform public health messaging.","Public health measures to reduce COVID-19 transmission include masking in public places, physical distancing, staying home when ill, avoiding high-risk locations, using a contact tracing app, and being willing to take a COVID-19 vaccine. However, adoption of these measures varies greatly. We aimed to improve health messaging to increase adherence to public health behaviours to reduce COVID-19 transmission by: 1) determining attitudes towards public health measures and current behaviours; 2) iden","2021","03","01","PLoS One","PloS one","Adolescent; Adult; Aged; Alberta; COVID-19; Contact Tracing; Female; Health Behavior; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; SARS-CoV-2; Social Media","Benham","Jamie L","Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada",NA
"84","33606033","10.1001/jamanetworkopen.2020.37640","Assessment of the Inclusion of Racial/Ethnic Minority, Female, and Older Individuals in Vaccine Clinical Trials.","Medical research has not equitably included members of racial/ethnic minority groups or female and older individuals. There are limited data on participant demographic characteristics in vaccine trials despite the importance of these data to current trials aimed at preventing coronavirus disease 2019. To investigate whether racial/ethnic minority groups and female and older adults are underrepresented among participants in vaccine clinical trials. This cross-sectional study examined data from co","2021","02","25","JAMA Netw Open","JAMA network open","Adult; African Continental Ancestry Group; Aged; Aged, 80 and over; Asian Continental Ancestry Group; Clinical Trials as Topic; Continental Population Groups; Cross-Sectional Studies; Ethnic Groups; European Continental Ancestry Group; Female; Humans; Male; Middle Aged; Oceanic Ancestry Group; Patient Selection; Sexism; Vaccines","Flores","Laura E","College of Allied Health Professions, University of Nebraska Medical Center, Omaha",NA
"85","33605892","10.2196/24341","Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021.","The Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) and Public Health England (PHE) are commencing their 54th season of collaboration at a time when SARS-CoV-2 infections are likely to be cocirculating with the usual winter infections. The aim of this study is to conduct surveillance of influenza and other monitored respiratory conditions and to report on vaccine uptake and effectiveness using nationally representative surveillance data extracted from ","2021","03","03","JMIR Public Health Surveill","JMIR public health and surveillance","COVID-19; computerized medical record systems; coronavirus infections; general practice; influenza; records as topic; sentinel surveillance; serology; virology; COVID-19; Clinical Protocols; Female; Humans; Influenza, Human; Male; Middle Aged; Population Surveillance; Public Health; Respiratory Tract Infections; United Kingdom; Vaccines","de Lusignan","Simon","Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom",NA
"86","33605848","10.2174/0929867328666210219142208","Advances of Inorganic Materials in the Detection and Therapeutic Uses Against Coronaviruses.","Coronaviruses (CoVs) are enveloped viruses with particle-like characteristics and a diameter of 60-140 nm, positively charged, and single-stranded RNA genomes which produce a major outbreak of human fatal pneumonia since the beginning of the 21st century. COVID-19 is currently considered as a continuous potential pandemic threat across the globe. Therefore, considerable efforts have been made to develop innovative methods and technologies for suppressing the spread of viruses as well as inactiva","2021","02","19","Curr Med Chem","Current medicinal chemistry","Coronavirus (CoV); RNA; metal complexes; metal-conjugates; metallic nanoparticles; sensing and inhibition.","Veerasamy","Sathish","Department of Chemistry, Bannari Amman Institute of Technology, Sathyamangalam - 638 401. India",NA
"87","33602838","10.1126/science.371.6531.768","The long road.",NA,"2021","03","08","Science","Science (New York, N.Y.)","Antibodies, Neutralizing; Antibodies, Viral; Asymptomatic Infections; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Communicable Disease Control; Humans; Immunity, Herd; Immunogenicity, Vaccine; Mass Vaccination; Mutation; Pandemics; SARS-CoV-2; T-Lymphocytes; Viral Load","Cohen","Jon","San Diego",NA
"88","33602071","10.2174/0929867328666210218182203","Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target.","Enveloped viruses belong to a large class of pathogens responsible for multiple serious diseases. Their spread into new territories has been the cause of major epidemics throughout human history, including the Spanish flu in 1918 and the latest COVID-19 pandemic. Thanks to their outer membrane, consisting essentially of host lipids, enveloped viruses are more resistant to enzymes, and are also less susceptible to host immune defenses than their naked counterparts. Therefore, the development of e","2021","02","19","Curr Med Chem","Current medicinal chemistry","broad-spectrum antiviral agents; emerging viruses.; entry; envelope; lipids; membrane; virus","Palombi","Nastasja","Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, . Italy",NA
"89","33600346","10.2196/23703","A Comprehensive Overview of the COVID-19 Literature: Machine Learning-Based Bibliometric Analysis.","Shortly after the emergence of COVID-19, researchers rapidly mobilized to study numerous aspects of the disease such as its evolution, clinical manifestations, effects, treatments, and vaccinations. This led to a rapid increase in the number of COVID-19-related publications. Identifying trends and areas of interest using traditional review methods (eg, scoping and systematic reviews) for such a large domain area is challenging. We aimed to conduct an extensive bibliometric analysis to provide a ","2021","03","13","J Med Internet Res","Journal of medical Internet research","2019-nCoV; COVID-19; SARS-CoV-2; bibliometric analysis; literature; machine learning; novel coronavirus disease; research; review","Abd-Alrazaq","Alaa","Division of Information and Computing Technology, College of Science and Engineering, Hamad Bin Khalifa University, Qatar Foundation, Doha, Qatar",NA
"90","33597145","10.1136/bmjopen-2020-044486","Association between cardiometabolic disease and severe COVID-19: a nationwide case-control study of patients requiring invasive mechanical ventilation.","The risks associated with diabetes, obesity and hypertension for severe COVID-19 may be confounded and differ by sociodemographic background. We assessed the risks associated with cardiometabolic factors for severe COVID-19 when accounting for socioeconomic factors and in subgroups by age, sex and region of birth. In this nationwide case-control study, 1.086 patients admitted to intensive care with COVID-19 requiring mechanical ventilation (cases), and 10.860 population-based controls matched fo","2021","02","25","BMJ Open","BMJ open","COVID-19; diabetes &amp; endocrinology; hypertension; intensive &amp; critical care; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; COVID-19; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Hospitalization; Humans; Hypertension; Male; Middle Aged; Obesity; Renal Insufficiency, Chronic; Respiration, Artificial; Risk Factors; Young Adult","Svensson","Per","Department of Clinical Science and Education, S..dersjukhuset, Karolinska Institutet, Stockholm, Sweden Per.Svensson@ki",NA
"91","33596958","10.1186/s12979-021-00219-y","Unanticipated efficacy of SARS-CoV-2 vaccination in older adults.","The rapidity with which vaccines against COVID-19 have been developed and tested is unprecedented. As classically the case with randomized clinical trials, many studies excluded older adults. However, given the early realisation that senior citizens were most highly susceptible to COVID, older individuals have been included in licensing trials under these unusual conditions. The recently published results from the Comirnaty Vaccine (BNT162b) trial unexpectedly documented that vaccine efficacy wa","2021","02","21","Immun Ageing","Immunity &amp; ageing : I &amp; A","COVID-19; Immunosenescence; Paradigm shift; SARS-CoV-2; Vaccination","Pawelec","Graham","Department of Immunology, University of T..bingen, T..bingen, Germany. graham.pawelec@uni-tuebingen",NA
"92","33596800","10.2174/1389557521666210217093004","A review on Remdesivir: A broad-spectrum antiviral molecule for possible COVID-19 treatment.","Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel coronavirus strain and the causative agent of COVID-19 was identified to have emerged in Wuhan, China, in December 2019 [1]. This pandemic situation and magnitude of suffering has led to global effort to find out effective measures for discovery of new specific drugs and vaccines to combat this deadly disease. In addition to many initiatives to develop vaccines for protective immunity against SARS-CoV-2, some of which are at v","2021","02","18","Mini Rev Med Chem","Mini reviews in medicinal chemistry","COVID-19; Coronavirus; Drug re-purposing; Remdesivir; Therapeutic molecules; therapeutics","Khazir","Jabeena","Department of Chemistry, Govt. Degree College (Boys) Pulwama, Kashmir-192301, J&amp",NA
"93","33596363","10.1056/NEJMe2102882","Audio Interview: Viral Variants and Covid-19.",NA,"2021","02","23","N Engl J Med","The New England journal of medicine","Animals; Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Disaster Planning; Disease Reservoirs; Evolution, Molecular; Genetic Variation; Humans; Information Dissemination; International Cooperation; Public Health Practice; SARS-CoV-2; United Kingdom; Virus Replication","Rubin","Eric J",NA,NA
"94","33596144","10.1089/gtmb.2020.0227","The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment.","Coronavirus disease 2019 (COVID-19) displays a broad spectrum of clinical presentations ranging from lack of symptoms to severe multiorgan system complications and death. Various laboratory assays have been employed in the diagnosis of COVID-19, including: nucleic acid-based tests; antigen tests; and serum testing for anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies. The disease can also be diagnosed based on suggestive clinical features and radiological findings. Unt","2021","02","22","Genet Test Mol Biomarkers","Genetic testing and molecular biomarkers","COVID-19; SARS-CoV-2; coronavirus; review; Adenosine Monophosphate; Alanine; Antiviral Agents; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Trials as Topic; Evolution, Molecular; Global Burden of Disease; Humans; Hydroxychloroquine; Mutation; Off-Label Use; Pandemics; RNA, Viral; SARS-CoV-2; Severity of Illness Index","Younis","Nour K","Department of Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon",NA
"95","33593976","10.1128/mBio.02492-20","Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.","The global coronavirus disease 2019 (COVID-19) pandemic has mobilized efforts to develop vaccines and antibody-based therapeutics, including convalescent-phase plasma therapy, that inhibit viral entry by inducing or transferring neutralizing antibodies (nAbs) against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (CoV2-S). However, rigorous efficacy testing requires extensive screening with live virus under onerous biosafety level 3 (BSL3) conditions, which l","2021","03","01","mBio","mBio","COVID-19; SARS-CoV-2; convalescent-phase plasma; neutralizing antibodies; viral neutralization assay; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; Enzyme-Linked Immunosorbent Assay; Humans; Neutralization Tests; SARS-CoV-2","Oguntuyo","Kasopefoluwa Y","Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA",NA
"96","33591649","10.32687/0869-866X-2021-29-1-5-13","[The organizational aspects of security support of participants of clinical testing of vaccine &quot;Gam-COVID-Vac&quot;].","The COVID-19 pandemic resulted in many aftermaths, economic crisis and extra charging of health care. The development of vaccine against SARS-nCoV-2 agent turned out as the priority task of world and Russian medicine and pharmaceutics. The investigation of efficiency and safety of vaccines can be prolonged for many years that can aggravate the observed crisis. Having regard to the global scope and speed of pandemic spreading, the vaccine &quot;Gam-COVID-Vac&quot; was registered with special proc","2021","02","18","Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med","Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny","COVID; Pharmakonadzor; clinical trial; independent committee; monitoring; safety; vaccine; COVID-19; COVID-19 Vaccines; Drug Monitoring; Humans; Pandemics; Russia; SARS-CoV-2","Naygovzina","N B","The State Budget Educational Institution of Higher Professional Education ..The A. E. Evdokimov Moscow State University of Medicine and Dentistry.., 127473, Moscow, Russia",NA
"97","33591423","10.1007/82_2020_230","mRNA-Based Vaccines and Mode of Action.","In the past 20 years, the mRNA vaccine technology has evolved from the first proof of concept to the first licensed vaccine against emerging pandemics such as SARS-CoV-2. Two mRNA vaccines targeting SARS-CoV-2 have received emergency use authorization by US FDA, conditional marketing authorization by EMA, as well as multiple additional national regulatory authorities. The simple composition of an mRNA encoding the antigen formulated in a lipid nanoparticle enables a fast adaptation to new emergi","2021","02","16","Curr Top Microbiol Immunol","Current topics in microbiology and immunology",NA,"Gergen","Janina","CureVac AG, T..bingen, Germany",NA
"98","33590417","10.1007/s10729-020-09542-0","From predictions to prescriptions: A data-driven response to COVID-19.","The COVID-19 pandemic has created unprecedented challenges worldwide. Strained healthcare providers make difficult decisions on patient triage, treatment and care management on a daily basis. Policy makers have imposed social distancing measures to slow the disease, at a steep economic price. We design analytical tools to support these decisions and combat the pandemic. Specifically, we propose a comprehensive data-driven approach to understand the clinical characteristics of COVID-19, predict i","2021","02","18","Health Care Manag Sci","Health care management science","COVID-19; Epidemiological modeling; Machine learning; Optimization","Bertsimas","Dimitris","Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA 02142, USA. dbertsim@mit","dbertsim@mit.edu"
"99","33585808","10.1016/j.bsheal.2021.02.001","An update to monoclonal antibody as therapeutic option against COVID-19.","With the number of COVID-19 cases soaring worldwide and limited vaccine availability for the general population in most countries, the monoclonal antibody (mAb) remains a viable therapeutic option to treat COVID-19 disease and its complications, especially in the elderly individuals. More than 50 monoclonal antibody-related clinical trials are being conducted in different countries around the world, with few of them nearing the completion of the third and fourth phase clinical trial. In view of ","2021","03","03","Biosaf Health","Biosafety and health","Antibody therapy; Corona virus; Monoclonal antibody; SARS-CoV-2; mAb","Deb","Paroma","Department of Virology, Dhaka Medical College, Dhaka, 1000, Bangladesh",NA
"100","33582489","10.1016/j.jri.2021.103285","Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery.","We report herein the longest-lasting study of SARS-CoV-2 antibody profile in pregnancy, from first trimester-infection to delivery. Seventeen out of 164 pregnant women tested positive for COVID-19. Throughout pregnancy, the neutralizing antibody titer remained stable, whilst a significant decline in the non-neutralizing antibodies was observed after 16 weeks of gestation. All the newborns of women who developed IgG antibodies showed the presence of the same antibodies in arterial cord blood. Kno","2021","03","08","J Reprod Immunol","Journal of reproductive immunology","Antibodies; COVID-19 immunology; COVID-19 vaccines; Pregnancy; SARS-CoV-2; Adult; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; Female; Humans; Immunoglobulin G; Longitudinal Studies; Pregnancy; Pregnancy Complications, Infectious; SARS-CoV-2","Cosma","Stefano","Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science, University of Turin, Turin, Italy",NA
"101","33582237","10.1016/j.annonc.2021.01.068","The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate.",NA,"2021","02","28","Ann Oncol","Annals of oncology : official journal of the European Society for Medical Oncology",NA,"Garassino","M C","Thoracic Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: Marina.Garassino@istitutotumori.mi","Marina.Garassino@istitutotumori.mi.it"
"102","33580113","10.1038/s41598-021-83166-4","Spatio-temporal distribution characteristics and influencing factors of COVID-19 in China.","In December 2019, corona virus disease 2019 (COVID-19) has broken out in China. Understanding the distribution of disease at the national level contributes to the formulation of public health policies. There are several studies that investigating the influencing factors on distribution of COVID-19 in China. However, more influencing factors need to be considered to improve our understanding about the current epidemic. Moreover, in the absence of effective medicine or vaccine, the Chinese governm","2021","02","26","Sci Rep","Scientific reports","COVID-19; China; Humans; Prevalence; Quarantine; Rural Population; Spatio-Temporal Analysis; Urban Population; Weather","Chen","Youliang","School of Civil and Surveying and Mapping Engineering, Jiangxi University of Science and Technology, Ganzhou, China. 9120010023@jxust.edu","9120010023@jxust.edu.cn"
"103","33579547","10.1016/j.clinthera.2021.01.014","The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?","In December 2020, the US Food and Drug Administration issued emergency use authorizations for two mRNA vaccines against coronavirus disease 2019. These vaccines represent an incredible scientific achievement and a major step in efforts to bring the global pandemic to a close. However, these vaccines create many logistical challenges that limit just how far-reaching their impact can be. This commentary reviews how these vaccines offer immunity, summarizes the Phase III trial results, and offers a","2021","02","15","Clin Ther","Clinical therapeutics","COVID-19; SARS CoV-2; Spike protein; mRNA vaccines","Jhaveri","Ravi","Division of Pediatric Infectious Diseases, Ann &amp","ravi.jhaveri@northwestern.edu"
"104","33578506","10.1515/jbcpp-2020-0208","Therapeutic clinical trials to combat COVID-19 pandemic in India: analysis from trial registry.","With the emergence of Novel corona virus, hunt for finding a preventive and therapeutic treatment options has already begun at a rapid pace with faster clinical development programs. The present study was carried out to give an insight of therapeutic interventional trials registered under clinical trial registry of India (CTRI) for COVID-19 pandemic. All trials registered under CTRI were evaluated using keyword &quot;COVID&quot; from its inception till 9th June 2020. Out of which, therapeutic in","2021","02","12","J Basic Clin Physiol Pharmacol","Journal of basic and clinical physiology and pharmacology","AYUSH; COVID-19; CTRI; India; clinical trials; corona virus; therapeutic interventions","Batta","Angelika","Department of Pharmacology, Faculty of Medical &amp",NA
"105","33578007","10.1016/j.ijid.2021.02.011","The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.","To evaluate the effects of probiotics on respiratory tract infection (RTI) a systematic review of randomized controlled trials (RCTs) from January 2010 to January 2020 was conducted. The PubMed, Google Scholar, Embase, Scopus, Clinicaltrials.gov, and International Clinical Trials Registry Platform databases were systematically searched for the following keywords: respiratory tract infection, probiotics, viral infection, COVID-19, and clinical trial. A total of 27 clinical trials conducted on 943","2021","03","14","Int J Infect Dis","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","COVID-19; Influenza vaccines; Probiotic; Randomized controlled trials; Respiratory tract infection","Darbandi","Atieh","Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran",NA
"106","33577086","10.1002/hep.31751","AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease.","The aim of this document is to provide a concise scientific review of the currently available COVID-19 vaccines and those in development, including mRNA, adenoviral vectors, and recombinant protein approaches. The anticipated use of COVID-19 vaccines in patients with chronic liver disease and liver transplant recipients is reviewed and practical guidance is provided for health care providers involved in the care of patients with liver disease and liver transplantation about vaccine prioritizatio","2021","02","13","Hepatology","Hepatology (Baltimore, Md.)","SARS-CoV-2; cirrhosis; coronavirus; immunosuppression; transplantation","Fix","Oren K","Elson S. Floyd College of Medicine, Washington State University, Spokane, WA",NA
"107","33574597","10.1038/d41586-021-00338-y","This COVID-vaccine designer is tackling vaccine hesitancy - in churches and on Twitter.",NA,"2021","02","19","Nature","Nature","Health care; Human behaviour; Public health; SARS-CoV-2; Society; Vaccines; African Continental Ancestry Group; American Natives; Animals; COVID-19 Vaccines; Clinical Trials as Topic; Communication; Fear; Health Education; Health Equity; Healthcare Disparities; Hispanic Americans; Humans; Religion; Research Personnel; Social Media; Trust; Vaccines, Synthetic; Volunteers","Subbaraman","Nidhi",NA,NA
"108","33571468","10.1016/S1470-2045(21)00017-6","SARS-CoV-2 vaccination and phase 1 cancer clinical trials.",NA,"2021","03","10","Lancet Oncol","The Lancet. Oncology",NA,"Yap","Timothy A","Investigational Cancer Therapeutics (Phase I Program), University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: tyap@mdanderson","tyap@mdanderson.org"
"109","33569389","10.3389/fmolb.2020.585899","A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic.","A new strain of coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 (COVID-19) pandemic was first detected in the city of Wuhan in Hubei province, China in late December 2019. To date, more than 1 million deaths and nearly 57 million confirmed cases have been recorded across 220 countries due to COVID-19, which is the greatest threat to global public health in our time. Although SARS-CoV-2 is genetically similar to other coronavir","2021","02","12","Front Mol Biosci","Frontiers in molecular biosciences","COVID-19; SARS-CoV-2; drugs; in silico approaches; vaccines","Sumon","Tofael Ahmed","Department of Fish Health Management, Sylhet Agricultural University, Sylhet, Bangladesh",NA
"110","33563499","10.1016/j.jhep.2021.01.032","EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.","According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in gener","2021","02","12","J Hepatol","Journal of hepatology","COVID-19; Cirrhosis; Influenza; Liver transplantation; SARS-CoV-2; Vaccine","Cornberg","Markus","Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany",NA
"111","33563270","10.1186/s12916-021-01923-8","Who should be prioritized for COVID-19 vaccination in China? A descriptive study.","All countries are facing decisions about which population groups to prioritize for access to COVID-19 vaccination after the first vaccine products have been licensed, at which time supply shortages are inevitable. Our objective is to define the key target populations, their size, and priority for a COVID-19 vaccination program in the context of China. On the basis of utilitarian and egalitarian principles, we define and estimate the size of tiered target population groups for a phased introducti","2021","02","22","BMC Med","BMC medicine","China; Novel coronavirus disease 2019; Target population; Vaccination; Adolescent; Aged; COVID-19; COVID-19 Vaccines; Child; China; Comorbidity; Ethical Theory; Female; Food Industry; Health Personnel; Health Priorities; Hospitalization; Humans; Immunization Programs; Infant; Influenza Vaccines; Influenza, Human; Intensive Care Units; Male; Middle Aged; Mortality; Nursing Homes; Pandemics; Patient Selection; Police; Policy Making; Pregnancy; SARS-CoV-2; Transportation; Vaccination; Young Adult","Yang","Juan","School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China",NA
"112","33562619","10.3390/vaccines9020127","Why It Is Important to Develop an Effective and Safe Pediatric COVID-19 Vaccine.","The need to cope with the medical, social, and economic storm due to the new coronavirus 2019 (COVID-19) pandemic as quickly as possible has led to the very rapid development of a huge number of vaccines. All these vaccines have been mainly developed in healthy adults and, in some cases, in the elderly. Children were marginally involved as, according to the clinical trial registry Clinical Trials.gov, only very few studies have included children among subjects to enroll, although just a few week","2021","03","14","Vaccines (Basel)","Vaccines","COVID-19; SARS-CoV-2; children; pediatric infectious diseases; vaccine","Principi","Nicola","Universit.. degli Studi di Milano, 20122 Milan, Italy",NA
"113","33559733","10.1007/s00403-021-02190-6","&quot;COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment&quot;.","We present the first reported cases of delayed inflammatory reactions (DIR) to hyaluronic acid (HA) dermal fillers after exposure to the COVID-19 spike protein. DIR to HA is reported to occur in the different scenarios including: secondary to poor injection technique, following dental cleaning procedures, following bacterial/viral illness, and after vaccination. In this report of 4 cases with distinct clinical histories and presentations: one case occured following a community acquired COVID-19 ","2021","02","11","Arch Dermatol Res","Archives of dermatological research","ACE receptor; ACE receptor inhibitor; ACE2; COVID-19; Delayed inflammatory reaction; Hyaluronic acid fillers; mRNA vaccine","Munavalli","Girish Gilly","Dermatology, Laser, and Vein Specialists of the Carolinas, PLLC, Charlotte, NC, USA. gmunavalli@carolinaskin","gmunavalli@carolinaskin.com"
"114","33558856","10.1016/j.idm.2021.01.004","A metapopulation network model for the spreading of SARS-CoV-2: Case study for Ireland.","We present preliminary results on an all-Ireland network modelling approach to simulate the spreading the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), commonly known as the coronavirus. In the model, nodes correspond to locations or communities that are connected by links indicating travel and commuting between different locations. While this proposed modelling framework can be applied on all levels of spatial granularity and different countries, we consider Ireland as a ","2021","02","16","Infect Dis Model","Infectious Disease Modelling","Compartmental model; Coronavirus; Network model; Non-pharmaceutical containment strategies; SARS-CoV-2","Humphries","Rory","School of Mathematical Sciences, University College Cork, Western Road, Cork, T12XF64, Ireland",NA
"115","33558296","10.1128/AAC.00200-21","Plitidepsin: a repurposed drug for the treatment of COVID-19.","Finding antivirals to reduce coronavirus disease 2019 (COVID-19) morbidity and mortality has been challenging. Large randomized clinical trials that aimed to test four repurposed drugs, hydroxychloroquine, lopinavir-ritonavir, interferon beta-1a, and remdesivir, have shown that these compounds lacked impact on the COVID-19 course. Although the Phase III COVID-19 vaccine trial results are encouraging, the search for effective COVID-19 therapeutics should not stop. Recently, plitidepsin (aplidin) ","2021","02","09","Antimicrob Agents Chemother","Antimicrobial agents and chemotherapy",NA,"Martinez","Miguel Angel","IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Aut..noma de Barcelona (UAB), Badalona, Spain mmartinez@irsicaixa","mmartinez@irsicaixa.es"
"116","33554155","10.1016/j.medj.2021.01.005","Stable neutralizing antibody levels six months after mild and severe COVID-19 episode.","Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. We conducted a longitudinal analysis on a prospective cohort of COVID-19 patients followed up for more than 6 months. Neutralizing activity was evaluated using HIV reporter pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody t","2021","02","11","Med (N Y)","Med (New York, N.Y.)","SARS-CoV-2; durability; humoral response; neutralization; pseudovirus","Pradenas","Edwards","IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916, Badalona, Catalonia, Spain",NA
"117","33553091","10.3389/fpubh.2020.591900","COVID-19 and Italian Healthcare Workers From the Initial Sacrifice to the mRNA Vaccine: Pandemic Chrono-History, Epidemiological Data, Ethical Dilemmas, and Future Challenges.","On March 11, 2020, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) outbreak a pandemic. Simultaneously, in Italy, in which the first case had occurred on February 18, the rigid phase of the lockdown began. The country has attracted worldwide attention, becoming at the same time a field of study both concerning the spread of the pandemic and advanced assessments of the effectiveness of political, public health, and therapeutic measures. The protagonists of the","2021","02","24","Front Public Health","Frontiers in public health","COVID-19; COVID-19 HCWs deaths; COVID-19 Italian physician's positivities and deaths; COVID-19 ethical dilemmas; COVID-19 future challenges; COVID-19 healthcare workers; COVID-19 mRNA vaccine; COVID-19: specialties of dead doctors; COVID-19; COVID-19 Vaccines; Communicable Disease Control; Health Personnel; Humans; Italy; Middle Aged; Personal Protective Equipment; Public Health; RNA, Messenger; SARS-CoV-2; Surveys and Questionnaires","Nioi","Matteo","Department of Medical Sciences and Public Health, Forensic Medicine Unit, University of Cagliari, Cagliari, Italy",NA
"118","33553084","10.3389/fpubh.2020.567337","Influence of Empathy Disposition and Risk Perception on the Psychological Impact of Lockdown During the Coronavirus Disease Pandemic Outbreak.","During the current COVID-19 pandemic, and especially in the absence of availability of an effective treatment or a vaccine, the main health measure is neither chemical nor biological, but behavioral. To reduce the exponential growth of infections due to the new coronavirus (SARS-CoV-2) and the resulting overburdening of the healthcare system, many European Countries, parts of the US and Switzerland gradually implemented measures of quarantine and isolation defined as lockdown. This consideration","2021","02","24","Front Public Health","Frontiers in public health","COVID-19; empathy; ethics; isolation; lockdown; prosocial; psychological distress; risk; Adaptation, Psychological; COVID-19; Empathy; Humans; Perception; Prospective Studies; Psychological Distress; Quarantine; Retrospective Studies; Risk Reduction Behavior; Surveys and Questionnaires","Grignoli","Nicola","Consultation-Liaison Psychiatry Service, Organizzazione Sociopsichiatrica Cantonale, Mendrisio, Switzerland",NA
"119","33552839","10.1007/s11901-021-00560-2","Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma.","This paper aims to summarize the data of recently completed and key ongoing clinical trials of systemic agents for advanced hepatocellular carcinoma (aHCC). In particular, the review focuses on ongoing checkpoint inhibitor combination trials and promising studies combining tyrosine kinase inhibitors with checkpoint inhibitors. The recently approved combination of atezolizumab and bevacizumab based on the IMbrave150 trial has shown the most potential with the highest overall survival of any syste","2021","02","10","Curr Hepatol Rep","Current hepatology reports","Atezolizumab; Bevacizumab; Clinical trials; Immunotherapy; Tyrosine kinase inhibitors","Aitcheson","Gabriella","Department of Internal Medicine, Jackson Memorial Hospital, Miami, FL USA",NA
"120","33552508","10.1002/cti2.1245","Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell generation in patients with acute COVID-19.","To predict the spread of coronavirus disease (COVID-19), information regarding the immunological memory for disease-specific antigens is necessary. The possibility of reinfection, as well as the efficacy of vaccines for COVID-19 that are currently under development, will largely depend on the quality and longevity of immunological memory in patients. To elucidate the process of humoral immunity development, we analysed the generation of plasmablasts and virus receptor-binding domain (RBD)-specif","2021","02","10","Clin Transl Immunology","Clinical &amp; translational immunology","SARS...CoV...2; antibody...secreting cell; memory B cell; plasmablast; virus...neutralising antibodies","Byazrova","Maria","National Research Center Institute of Immunology of Federal Medical Biological Agency of Russia Moscow Russia",NA
"121","33550983","10.1186/s13048-021-00772-6","COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?","Improving early diagnosis along with timely and effective treatment of COVID-19 are urgently needed. However, at present, the mechanisms underlying disease spread and development, defined prognosis, and immune status of patients with COVID-19 remain to be determined. Patients with severe disease state exhibit a hyperinflammatory response associated with cytokine storm syndrome, hypercoagulability, and depressed cell-mediated immunity. These clinical manifestations, sharing similar pathogenesis, ","2021","02","17","J Ovarian Res","Journal of ovarian research","COVID-19; Corticosteroids; Immunopathology; Interleukin-6; Ovarian cancer; Oxidative stress; Resistance; Tolerance; Adrenal Cortex Hormones; Aspirin; COVID-19; COVID-19 Vaccines; Cytokine Release Syndrome; Female; Humans; Immunization, Passive; Inflammation; Interleukin-6; Necrosis; Ovarian Neoplasms; Oxidative Stress","Macci..","Antonio","Department of Gynecologic Oncology, Businco Hospital, &quot","antoniomaccio56@gmail.com"
"122","33550776","10.4235/agmr.21.0011","Review of COVID-19 vaccines and its evidence in older adults.","The SARS-CoV-2 virus resulted in a global pandemic and significant loss of lives. Older people are vulnerable to COVID-19 infections and complications, thus are a priority group to receive COVID-19 vaccines. In this review, COVID-19 vaccine considerations for older adults are discussed. General concepts of vaccine effectiveness in older adults are described, particularly immune senescence and vaccine development approaches to improve immunogenicity. The types of COVID-19 vaccine platforms are de","2021","02","08","Ann Geriatr Med Res","Annals of geriatric medicine and research","COVID-19; older adults; vaccine","Teo","Shyh Poh","Department of Internal Medicine, Raja Isteri Pengiran Anak Saleha (RIPAS) Hospital, Bandar Seri Begawan, Brunei Darussalam, BA1710",NA
"123","33550606","10.5694/mja2.50930","Not in my backyard: COVID-19 vaccine development requires someone to be infected somewhere.",NA,"2021","03","09","Med J Aust","The Medical journal of Australia","COVID-19; Clinical trials as topic; Infectious diseases; Respiratory tract infections; Vaccines; Australia; COVID-19; COVID-19 Vaccines; Drug Development; Humans; Incidence; Pandemics; SARS-CoV-2","Heriot","George S","Monash University, Melbourne, VIC",NA
"124","33549712","10.1016/j.gene.2021.145471","The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19.","In addition to causing health concerns, the new coronavirus has been considered in the world with its unknown mechanism of physiopathogenesis and long-term effects after patient recovery. Pulmonary, renal, hepatic and cardiac complications have been reported so far. Beside the researchers' focus on finding vaccines and using conventional therapies, cell-based therapy might be an effective therapeutic strategy. The use of mesenchymal stem cells (MSCs) is one of the options due to their immunomodu","2021","03","08","Gene","Gene","Covid 19; Mesenchymal stem cells; Tissue regeneration; Treatment; COVID-19; Humans; Immunomodulation; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Practice Guidelines as Topic; SARS-CoV-2","Saburi","Ehsan","Medical Genetics and Molecular Medicine Department, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran",NA
"125","33549288","10.1016/j.cnur.2020.10.007","Herbal Medication to Enhance or Modulate Viral Infections.","Viral infections and their emergence continue to pose a threat to human lives. Up to the present, there are limited numbers of vaccines that effectively work and few antivirals licensed for use in clinical practice. Added to this is the increase in antiviral resistance, meaning that drugs that do work are at risk of reduced efficacy. The recent global pandemic of coronavirus 2019 has provided evidence for the risk of a preventative vaccination and effective treatment of viruses' subsequent conse","2021","02","10","Nurs Clin North Am","The Nursing clinics of North America","COVID-19; Gastrointestinal; Herbs; Immune; Respiratory; Viral; Advanced Practice Nursing; COVID-19; Humans; Nurse's Role; Phytotherapy; Randomized Controlled Trials as Topic; Virus Diseases","Tahmasbi","Sherin F","Tennessee State University, School of Nursing, 3500 John A. Merritt Boulevard, Campus Box 9590, Nashville, TN 37209, USA. Electronic address: stahmasb@tnstate","stahmasb@tnstate.edu"
"126","33549263","10.1016/j.mayocp.2020.11.024","COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine.","Coronavirus disease 2019 (COVID-19) is characterized by heterogeneity in susceptibility to the disease and severity of illness. Understanding inter-individual variation has important implications for not only allocation of resources but also targeting patients for escalation of care, inclusion in clinical trials, and individualized medical therapy including vaccination. In addition to geographic location and social vulnerability, there are clear biological differences such as age, sex, race, pre","2021","02","25","Mayo Clin Proc","Mayo Clinic proceedings","Biological Variation, Population; COVID-19; COVID-19 Testing; Genetic Predisposition to Disease; Humans; Precision Medicine; Severity of Illness Index; Treatment Outcome","Pereira","Naveen L","Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address: pereira.naveen@mayo","pereira.naveen@mayo.edu"
"127","33548194","10.1016/S1473-3099(20)30987-7","Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.","A vaccine against COVID-19 is urgently needed for older adults, in whom morbidity and mortality due to the disease are increased. We aimed to assess the safety, tolerability, and immunogenicity of a candidate COVID-19 vaccine, CoronaVac, containing inactivated SARS-CoV-2, in adults aged 60 years and older. We did a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial of CoronaVac in healthy adults aged 60 years and older in Renqiu (Hebei, China). Vaccine or placebo was given by","2021","02","28","Lancet Infect Dis","The Lancet. Infectious diseases",NA,"Wu","Zhiwei","Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China",NA
"128","33547453","10.1038/s41562-021-01056-1","Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA.","Widespread acceptance of a vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be the next major step in fighting the coronavirus disease 2019 (COVID-19) pandemic, but achieving high uptake will be a challenge and may be impeded by online misinformation. To inform successful vaccination campaigns, we conducted a randomized controlled trial in the UK and the USA to quantify how exposure to online misinformation around COVID-19 vaccines affects intent to vaccinate to prot","2021","03","09","Nat Hum Behav","Nature human behaviour",NA,"Loomba","Sahil","Department of Mathematics, Imperial College London, London, UK",NA
"129","33547431","10.1038/d41586-021-00315-5","Could mixing COVID vaccines boost immune response?",NA,"2021","02","19","Nature","Nature","Immunology; Infection; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Industry; Humans; Immunization, Secondary; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Synthetic","Ledford","Heidi",NA,NA
"130","33545094","10.1016/S0140-6736(21)00234-8","Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.","A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial. We did a randomised, double-blind, placebo-controlled, phase 3 trial at 25 hospitals and polyclinics in Moscow, Russia. We included participants aged at ","2021","02","26","Lancet","Lancet (London, England)","Adult; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Double-Blind Method; Female; Humans; Immunization, Secondary; Injections, Intramuscular; Male; Middle Aged; Moscow; Spike Glycoprotein, Coronavirus; Vaccines, Synthetic","Logunov","Denis Y","Federal State Budget Institution &quot","ldenisy@gmail.com"
"131","33545014","10.1080/21645515.2020.1865774","Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.","COVID-19 is an international public health emergency in need of effective and safe vaccines for SARS-CoV-2. A systematic review has been done to analyze the availability, development and status of new COVID-19 vaccine candidates as well as the status of vaccines for other diseases that might be effective against SARS-CoV-2 infection. PubMed, MEDLINE, EMBASE, Science Direct, Google Scholar, Cochrane library, ClinicalTrials.gov, Web of Science and different trial registries were searched for curre","2021","02","05","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","SARS-CoV-2; clinical trial; coronavirus; covid-19; vaccine candidates; vaccine development","Bhatta","Mihir","Division of Virology, ICMR-National Institute of Cholera and Enteric Diseases , Kolkata, India",NA
"132","33544720","10.1371/journal.pcbi.1008686","SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.","The novelty of new human coronavirus COVID-19/SARS-CoV-2 and the lack of effective drugs and vaccines gave rise to a wide variety of strategies employed to fight this worldwide pandemic. Many of these strategies rely on the repositioning of existing drugs that could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we presented a new network-based algorithm for drug repositioning, called SAveRUNNER (Searching off-lAbel dRUg aNd NEtwoRk), which predicts drug-","2021","02","25","PLoS Comput Biol","PLoS computational biology","Algorithms; Antiviral Agents; COVID-19; Clinical Trials as Topic; Comorbidity; Computational Biology; Computer Simulation; Drug Discovery; Drug Evaluation, Preclinical; Drug Repositioning; Host Microbial Interactions; Humans; Pandemics; Protein Interaction Maps; SARS-CoV-2","Fiscon","Giulia","Institute for Systems Analysis and Computer Science &quot",NA
"133","33544024","10.1080/21645515.2021.1872344","Anticipated reduction in COVID-19 mortality due to population-wide BCG vaccination: evidence from Germany.","Bacillus Calmette-Gu..rin (BCG) vaccine is known to have &quot;bystander benefits&quot; in protecting against heterologous infections; interim analysis of the &quot;ACTIVATE&quot; trial shows protection against respiratory infections in the elderly population. Epidemiologic studies suggest a potential benefit of BCG vaccination on COVID-19 outcomes. Differential past BCG vaccination policies between the former East and West German states provides a unique natural experiment to assess the potenti","2021","02","05","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","BCG; CoMo model; Heterologous effects; SARS-CoV-2; mathematical model; model-based experiment; non-pharmaceutical-interventions","Mar..n-Hern..ndez","Daniela","Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, Belfer Research Building , New York, NY, USA",NA
"134","33542114","10.1126/science.371.6529.548","Two new vaccines deliver good and bad news for the pandemic.",NA,"2021","02","23","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Mass Vaccination; Pandemics; SARS-CoV-2; South Africa","Cohen","Jon","With reporting by Meredith Wadman",NA
"135","33539728","10.1016/S0140-6736(21)00198-7","COVID-19 vaccine research and the trouble with clinical equipoise.",NA,"2021","02","24","Lancet","Lancet (London, England)","COVID-19; COVID-19 Vaccines; Drug Development; Humans; Randomized Controlled Trials as Topic; SARS-CoV-2; Therapeutic Equipoise","Friesen","Phoebe","Biomedical Ethics Unit, McGill University, Montreal, QC, Canada",NA
"136","33539333","10.15585/mmwr.mm7005e1","Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program - United States, December 14, 2020-January 14, 2021.","In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) were authorized for emergency use in the United States for the prevention of coronavirus disease 2019 (COVID-19).* Because of limited initial vaccine supply, the Advisory Committee on Immunization Practices (ACIP) prioritized vaccination of health care personnel<sup>...</sup> and residents and staff members of long-term care facilities (LTCF) during the first phase of the U.S. COVID-19 vaccination program (1). Both vaccines re","2021","02","05","MMWR Morb Mortal Wkly Rep","MMWR. Morbidity and mortality weekly report","Adolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Continental Population Groups; Ethnic Groups; Female; Humans; Immunization Programs; Male; Middle Aged; Program Evaluation; United States; Vaccination; Young Adult","Painter","Elizabeth M",NA,NA
"137","33539332","10.15585/mmwr.mm7005e2","Early COVID-19 First-Dose Vaccination Coverage Among Residents and Staff Members of Skilled Nursing Facilities Participating in the Pharmacy Partnership for Long-Term Care Program - United States, December 2020-January 2021.","Residents and staff members of long-term care facilities (LTCFs), because they live and work in congregate settings, are at increased risk for infection with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1,2). In particular, skilled nursing facilities (SNFs), LTCFs that provide skilled nursing care and rehabilitation services for persons with complex medical needs, have been documented settings of COVID-19 outbreaks (3). In addition, residents of LTCFs might be at increa","2021","02","05","MMWR Morb Mortal Wkly Rep","MMWR. Morbidity and mortality weekly report","Aged; COVID-19; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Humans; Long-Term Care; Pharmacy; Program Evaluation; Public-Private Sector Partnerships; Skilled Nursing Facilities; United States; Vaccination Coverage","Gharpure","Radhika",NA,NA
"138","33539309","10.2196/23231","Comparing Public Perceptions and Preventive Behaviors During the Early Phase of the COVID-19 Pandemic in Hong Kong and the United Kingdom: Cross-sectional Survey Study.","Given the public health responses to previous respiratory disease pandemics, and in the absence of treatments and vaccines, the mitigation of the COVID-19 pandemic relies on population engagement in nonpharmaceutical interventions. This engagement is largely driven by risk perception, anxiety levels, and knowledge, as well as by historical exposure to disease outbreaks, government responses, and cultural factors. The aim of this study is to compare psychobehavioral responses in Hong Kong and the","2021","03","14","J Med Internet Res","Journal of medical Internet research","COVID-19; Hong Kong; United Kingdom; anxiety; behavioural response; comparative; novel coronavirus; pandemic; risk perceptions","Bowman","Leigh","MRC Centre for Global Infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College, London, United Kingdom",NA
"139","33539177","10.2105/AJPH.2020.306166","Employer-Mandated Vaccination for COVID-19.","When the US Food and Drug Administration (FDA) decided to grant emergency use authorization (EUA) for the first two vaccines for COVID-19, the United States' response to the pandemic entered a new phase. Initially, the greatest challenge is having enough doses of vaccine and administering them to all who want it. Yet even while many wait expectantly for their turn to be vaccinated, a significant minority of Americans are hesitant. Lack of information or misinformation about the vaccine, a long-s","2021","02","04","Am J Public Health","American journal of public health",NA,"Rothstein","Mark A","Mark A. Rothstein is with Institute for Bioethics, Health Policy and Law, University of Louisville School of Medicine, Louisville, KY. Wendy E. Parmet is with School of Law, Northeastern University, Boston, MA. Dorit Rubinstein Reiss is with University of California Hastings College of the Law, San Francisco. Wendy E. Parmet is also an AJPH associate editor",NA
"140","33538178","10.2217/fon-2020-0754","The right immune-modulation at the right time: thymosin ..1 for prevention of severe COVID-19 in cancer patients.","We presented the rationale for the use of thymosin ..1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective, multicenter, open-label, Phase II randomized study, currently in its start-up phase..(Eudract no. 2020-006020-13). We aim to offer new hope for this incurable disease, especially to frail patient population, such as patients with cancer. The hypothesis of an effective prophylactic approach to C","2021","02","25","Future Oncol","Future oncology (London, England)","COVID-19; SARS-CoV-2; cancer; cancer patients; prevention; prophylaxis; vaccination; Adjuvants, Immunologic; COVID-19; Clinical Trials, Phase II as Topic; Humans; Neoplasms; Randomized Controlled Trials as Topic; Research Design; SARS-CoV-2; Thymalfasin","Bersanelli","Melissa","Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, Parma, 43126, Italy",NA
"141","33536319","10.1136/bmjopen-2020-042034","Country-level determinants of the severity of the first global wave of the COVID-19 pandemic: an ecological study.","We aimed to identify the country-level determinants of the severity of the first wave of the COVID-19 pandemic. Ecological study of publicly available data. Countries reporting &gt;25 COVID-19 related deaths until 8 June 2020 were included. The outcome was log mean mortality rate from COVID-19, an estimate of the country-level daily increase in reported deaths during the ascending phase of the epidemic curve. Potential determinants assessed were most recently published demographic parameters (po","2021","02","10","BMJ Open","BMJ open","epidemiology; infectious diseases; public health; Adult; Africa; Age Factors; Aged; Air Pollution; Americas; Asia; Body Mass Index; COVID-19; Diabetes Mellitus; Europe; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Pandemics; Population Density; SARS-CoV-2; Smoking; Social Determinants of Health; Temperature; Travel; Young Adult","Pana","Tiberiu A","Institute of Applied Health Sciences, School of Medicine, Medical Sciences &amp","tiberiupana12@gmail.com"
"142","33535811","10.1177/1740774520988244","COVID-19 vaccine trials: The use of active controls and non-inferiority studies.","Recently emerging results from a few placebo-controlled randomized trials of COVID-19 vaccines revealed estimates of 62%-95% relative reductions in risk of virologically confirmed symptomatic COVID-19 disease, over approximately 2-month average follow-up period. Additional safe and effective COVID-19 vaccines are needed in a timely manner to adequately address the pandemic on an international scale. Such safe and effective vaccines would be especially appealing for international deployment if th","2021","03","04","Clin Trials","Clinical trials (London, England)","COVID-19; SARS-CoV-2; active comparator; margin; non-inferiority; placebo-controlled; vaccines","Fleming","Thomas R","Department of Biostatistics, University of Washington, Seattle, WA, USA",NA
"143","33535239","10.1093/infdis/jiaa637","Lessons From Bacille Calmette-Gu..rin for SARS-CoV-2 Vaccine Candidates.","Developers of severe acute respiratory syndrome coronavirus 2 vaccines should consider some of the lessons from a &quot;new&quot; vaccine introduced in 1921, namely bacille Calmette-Gu..rin.","2021","02","25","J Infect Dis","The Journal of infectious diseases","BCG; COVID-19; SARS-CoV-2; vaccine; Animals; BCG Vaccine; COVID-19; COVID-19 Vaccines; Humans; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2; Tuberculosis","Behr","Marcel A","Department of Medicine, McGill University, Montreal, Quebec, Canada",NA
"144","33532780","10.1101/2021.01.25.428136","mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge.","The mRNA-1273 vaccine was recently determined to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interim Phase 3 results. Human studies, however, cannot provide the controlled response to infection and complex immunological insight that are only possible with preclinical studies. Hamsters are the only model that reliably exhibit more severe SARS-CoV-2 disease similar to hospitalized patients, making them pertinent for vaccine evaluation. We demonstrate that","2021","02","03","bioRxiv","bioRxiv : the preprint server for biology",NA,"Meyer","Michelle",NA,NA
"145","33531462","10.1038/s41392-021-00481-y","Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.","In response to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, over 200 vaccine candidates against coronavirus disease 2019 (COVID-2019) are under development and currently moving forward at an unparalleled speed. The availability of surrogate endpoints would help to avoid large-scale filed efficacy trials and facilitate the approval of vaccine candidates, which is crucial to control COVID-19 pandemic. Several phase 3 efficacy trials of COVID-19 vaccine candidates are ","2021","02","22","Signal Transduct Target Ther","Signal transduction and targeted therapy","Biomarkers; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Pandemics; SARS-CoV-2","Jin","Pengfei","Department of Vaccine Clinical Evaluation, Jiangsu Province Center for Disease Control and Prevention, Nanjing, China",NA
"146","33531342","10.1136/bmj.n309","Covid-19: Russian vaccine efficacy is 91.6%, show phase III trial results.",NA,"2021","02","04","BMJ","BMJ (Clinical research ed.)",NA,"Mahase","Elisabeth","The BMJ",NA
"147","33527084","10.1007/s40808-021-01118-3","Statistical data analysis of risk factor associated with mortality rate by COVID-19 pandemic in India.","The coronavirus is an infection caused by severe acute respiratory syndrome (SARS) coronavirus, known as SARS-CoV-2. It was first determined in Wuhan, China in December 2019. WHO named this virus as COVID-19. Virologist says that COVID-19 is similar to SARS and MARS virus. This deadly disease affected worldwide economically, hammering people lifestyle and also the environmental condition. After a few months, there is no vaccine to build the barricade between this virus and life. Many countries h","2021","02","03","Model Earth Syst Environ","Modeling earth systems and environment","COVID-19 pandemic; Global issues; India; Lockdown; Mortality rate; People health","Halder","Bijay","Department of Remote Sensing and GIS, Vidyasagar University, Midnapore, India",NA
"148","33526007","10.1186/s12575-020-00141-5","Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review.","COVID-19, a pandemic of the 21st century..caused by novel coronavirus SARS-CoV-2..was originated from China and shallowed..world economy and human resource. The medical..cures..via herbal treatments, antiviral drugs, and vaccines still in progress, and studying rigorously. SARS-CoV-2 is more virulent than its ancestors due to evolution in..the spike protein(s), mediates viral attachment to the host's membranes. The SARS-CoV-2 receptor-binding spike domain associates itself with human angiotensin","2021","02","06","Biol Proced Online","Biological procedures online","ACE-2 receptor; COVID-19; Coronavirus; Drug repurposing","Choudhary","Jyoti","Department of Microbiology, Chinmaya Degree College (Hemwati Nandan Bahuguna Garhwal University, Srinagar, Garhwal, Uttarakhand), Haridwar, Uttarakhand, 249401, India",NA
"149","33525860","10.5217/ir.2020.00156","Management of inflammatory bowel disease in the COVID-19 era.","During the coronavirus disease 2019 (COVID-19) pandemic, many unpredictable changes have occurred in the medical field. Risk of COVID-19 does not seem to increase in patients with inflammatory bowel disease (IBD) considering based on current reports. Current medications for IBD do not increase this risk; on the contrary, some of these might be used as therapeutics against COVID-19 and are under clinical trial. Unless the patients have confirmed COVID-19 and severe pneumonia or a high oxygen dema","2021","02","02","Intest Res","Intestinal research","COVID-19; Coronavirus; Inflammatory bowel disease; SARS-CoV-2","Kim","Kyeong Ok","Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea",NA
"150","33525208","10.23750/abm.v91i4.10377","The Italian Covid-19 Phase 2 in Piacenza: results of the first semester of 2020 and future prospective of new orthopedics surgical procedures.","During the pandemic, Piacenza's Orthopedic and Traumatology Dep. firstly dealt with the emergency with the complete closure of all the elective surgical and outpatient activities.As general population, also healthcare workers were affected by Coronavirus, increasing difficulties of epidemic management.The aim of our study is to evaluate the activity trend of the first 6months of 2020 in our hospital.Data will be compared to the two semesters of 2019, in order to have two objective samples. We re","2021","03","08","Acta Biomed","Acta bio-medica : Atenei Parmensis","COVID-19; Forecasting; Hospitals; Humans; Italy; Orthopedic Procedures; Retrospective Studies; Time Factors","Maniscalco","Pietro","Orthopedics and Traumatology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy. P.Maniscalco@ausl.pc","P.Maniscalco@ausl.pc.it"
